focu individu call given macro volatil
expect continu debat implic potenti
drug price reform remain encourag sector
innov highlight ow-rat alxn/bmrn large-cap
imgn/irwd/exel smid-cap
call macro theme across sector
substanti dissimilar headwind relat potenti drug
price reform creat uncertainti despit biotech valuat near year
low smid initi buoy expect
pressur rise rate lack strateg action thu believ clear
clinic catalyst regulatori updat drive upsid downsid
repres best strategi gener return large-cap favor
alexion biomarin alexion see approv februari
fast launch drive long-term stabil busi inflect termin
multipl higher biomarin see posit result two pivot studi
potenti indic hemophilia achondroplasia drive
higher smid-cap favor ow-rat sarepta limb girdl data
clear path approv dmd genetherapi derisk dmd manufactur
drive upsid immunomed see approv
fast launch mtnbc key driver gw pharma see progress
epidiolex launch major driver neurocrin see quarterli
updat launch tardiv dyskinesia expand salesforc
potenti upsid phase data congenit adren hyperplasia
move higher see potenti downsid uw-rat
believ risk phiii forward studi could fail
ironwood expect greater pressur linzess competit
subsequ price risk see downsid cabometyx
sale result greater-than-expect competit addit compet
combin data rcc
could provid meaning updat key investor debat
celgen gilead alexion investor remain concern
biosimilar second largest product neulasta could headwind
manag overcom believ manag manag
declin consensu expect onpro succeed maintain neulasta
share outsiz downsid risk lose
enbrel trial sandoz expect rule updat
relat tecfidera ip progress alzheim studi drive
percept celgen manag execut launch product
key especi refil ozanimod initi fredratinib file
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
gilead new ceo strategi key pipelin readout prep nash
major driver investor percept final alexion
launch ip updat soliri repres key investor view
sustain franchis
smid-cap debat remain focus clinic progress potenti
debat meaning updat could come alnylam
beigen sarepta dbv evelo rubiu
alnylam expect multipl pivot studi updat potenti
regulatori updat givosiran key phiii studi
margetuximab breast cancer read dbv like
fda advisori committe potenti approv viaskin could drive dbvt
continu launch arikac major percept
driver initi quarter potenti drive beigen head-
to-head data versu ibrutinib wm could potenti drive bgne /-
initi phiii data earli could major
impact like drive sarepta dmd genetherapi data
potenti data competitor solid cover could
major impact investor percept evelo rubiu initi
data platform could signific impact investor view
viabil platform pipelin program potenti drive
industri view
tail two year one smid-cap dramat outperform
investor await consolid larg cap tax reform open signific
cash reserv second one smid-cap revers cours investor fret
govern price action rise interest rate flight qualiti
benefit larg cap expect wave materi
pressur smid turn see innov
key theme could drive biopharma higher mani smid
high larg cap manag team key pushback high valuat
reason expect pace acceler need growth
still major issu larg cap second innov remain major
readout includ nash initi platform dataset evelo
rubiu ipo face pressur solid data major
platform stori could inflect investor percept ultim believ
fundament driver prevail realist polit macro
headwind sector face expect develop around drug price
continu domin polit discuss like lead volatil across
sector believ meaning chang unlik margin chang
could outsiz impact singl name possibl
tailwind headwind balanc head
tailwind repres attract valuat access cash achiev estim
potenti increas activ
valuat remain attract absolut basi absolut basi
forward price-to-earnings ev/ebitda multipl well histor level
forward price-to-earnings current discount market level seen
sinc ev/ebitda sector trade discount broader
market thu compar broader market biotech remain attract
valuat also attract rel pharma healthcar
peer rel basi biotech forward price-to-earnings forward ev/ebitda
discount pharma healthcar first time sinc last time
recent decad valuat in-lin healthcar sector
free cash flow yield also well market dramat
improv yield last decad yield current
premium pharma healthcar overal market sector abl
larg hold out-performance sinc may late-cycl
trend manag team move invest new product cycl posit
biotech well invest cycl
estim gener appear achiev larg cap coverag univers
top bottom line estim gener line consensu
appear achiev would note forecast non-cash tax rate
manag guid call vertex start
like reflect consensu major driver delta estim
exhibit morgan stanley research consensu revenu ep estim
phiii data readout regulatori catalyst skew posit
remain dearth major phiii dataset larg cap coverag
except gilead mani key phiii dataset could inflect individu
stock highlight dataset beigen sarepta biomarin
gilead key late-stag driver initi interim futil data
omecamtiv mecarbil could key driver percept amgen/cytokinet
regulatori catalyst key approv alexion dbv could
drive investor percept key launch
exhibit final interim phiii data readout
innov remain import tailwind sector turn mani
key themat investor focus deliv first
pivot dataset exampl bring addit gene therapi
dataset larg indic dmd hemophilia initi crispr data initi
updat mrna addit new modal target therapi
administ via red blood cell rubiu human microbiom evelo
cellular senesc initi platform derisk data
major advanc remain key driver investor interest biotech thu
clear dataset highlight innov potenti sector remain key
fda open flexibl regard novel product registr conjunct
continu stream innov fda support new therapi
support regul allow pipelin advanc faster
indic expand rapidli key exampl includ loxo
sarepta fda approv new
drug compar fda commission scott gottlieb
work improv way fda review product tri
flexibl way fda look dataset commission gottlieb call
addit increas effort review gene therapi product
fda open discuss creation new endpoint
headwind includ reinflect polit develop relat drug price
increas biosimilar activ threaten long-term revenu tail interest rate
sensit sector
price headwind expect persist potenti demo
project part b/d trump administr focus drug price
trump administr set sever explicit propos could impact
industri inde alreadi chang industri behavior
limit price increas key propos administr suggest demo
project medicar part could link drug price intern
refer system exampl calcul impact price cut part
 tabl demo project relat medicar part
spend potenti includ part reform part larger
congression would expect risk relat govern price exposur
remain key headwind
exhibit price volum summari
biosimilar still repres structur headwind industri pace
biosimilar develop increas significantli avail
new approv near-term impact biosimilar
continu stall due litig entrench brand competitor new
entri could repres key headwind industri growth particular
focus biosimilar impact neulasta
exhibit biosimilar approv fda ema
epogen procrit
epogen procrit
exhibit biosimilar file fda ema
exhibit biosimilar late stage develop
exhibit neupogen epogen price decay forecast mse
exhibit neupogen epogen volum decay forecast mse
still rate sensit sector biotech valuat highli
depend larg termin valu driver result biotech valuat
highli sensit chang discount rate us equiti market whole
neg exposur steepen yield curv accord global
equiti strategi team increas yield curv slope associ
expect market return continu expect rate increas
highlight known clear headwind
exhibit pharma yield curv level sensit
key drive factor behind expect remain place slow
top-line growth larg cap persist highlight need late-stag
asset could inflect growth larg cap ceo consist note smid
valuat smid ceo expect high limit appetit
smid valuat becom reason late larg cap need
becom acut could repres inflect
us larg cap biopharma signific cash past year us pharma
seen steadi increas cash us biotech saw gradual increas cash
total cash posit us biotech compani saw sharp increas
drop year pharma industri europ japan also
increas cash posit time began drop
seemingli stabil larg cash reserv coupl tax reform led
much specul given dynam place larg cap continu
signific capac
exhibit total posit pharma
recent deal activ focus later stage asset versu prior year
limit howev deal complet either late-stag
phiii market product someth differ deal
complet previous would expect trend similar
term asset like acquir
ipo hangov
robust year ipo secondari activ year
involv deal ipo fo follow-on activ significantli slow
deal ipo fo activ return increas deal
deal activ return level deal led increas
ipo fo given smid cap market environ record equiti rais
believ past year like reproduc importantli deal activ
increas step-up last privat round ipo increas histor
median last time step-up increas time period
exhibit histor number biotech ipo follow-on
ipo perform stall coupl rise step-up valu could
signal limit number deal believ limit deal activ
could help investor focu fundament current public compani
could ultim posit sign public privat market
exhibit return biotech ipo
thomson reuter morgan stanley research note delist compani exclud earli spike return ipo
relat stock price perform
anticip final decis inter part review
statutori timelin one year ptab issu final judgement institut
ipr extens possibl unlik highlight case
relat patent way biosimilar develop note
suprem court rule ipr constitut case oil state vs
green energi group et al determin inter part review process
violat either articl seventh amend thu remov overhang
current case see institut decis ipr celgen
revlimid earli februari tecfidera mid janurari ipr
biggest headlin risk institut believ celg could potenti
convers ipr institut could potenti
author materi act capac attorney hold
materi intend either legal opinion legal
advic inform provid herein provid possibl outcom
probabl outcom result legal disput controversi depend
varieti factor includ limit parti histor relationship law
pertain case rel litig talent trial locat juri composit judg
composit investor contact legal advisor issu law relat
subject matter materi
exhibit final decis institut ipr decid
treatment hematolog malign
therapi autoimmun diseas patient
inadequ respons tnf- inhibitor
therapi autoimmun diseas patient
inadequ respons tnf- inhibitor
method make human antibodi
treatment antibodi
method make human antibodi
combin therapi b-cell lymphoma compris
administr antibodi
treatment hematolog malign associ
deuter deriv ruxolitinib
method treat medic condit induc
involv administ antagonist
patient afflict condit
method treat medic condit induc
involv administ antagonist
patient afflict condit
year term potenit join anoth ipr deadlin extens
method treat myelodysplast syndrom
combin therapi use lenalidomid azacitidin
method use
treatment manag
method treat myelodysplast syndrom use
method treatment multipl myeloma use
treatment multipl sclerosi
heavi chain mutant lead improv immunoglobulin
industri debat view
happen downsid price
debat trump administr attempt amend medicar pay
drug review medicar divid four part part involv
hospit coverag includ inpati visit special nurs facil hospic
home health servic part pertain medic coverag includ doctor
clinic lab servic outpati prevent care servic home healthcar
physic occup therapi surgic fee suppli part also known
medicar advantag combin part part cover prescript drug
coverag part drug deliv physician offic part drug pick
pharmaci two medicar part would impact biopharma
part b-target intern price index demo project trump
administr propos demo project would cover approxim half
us set medicar payment amount select part drug
phase close align intern price via intern
price payment model pleas see previou note
part d-target though potenti chang protect class medicar
advantag demo protect class group drug part plan must
antipsychot antiretrovir immunosuppress result
protect drug typic insul price pressur
propos rule allow plan exclud formulari drug class
price increas greater inflat well new drug formul
signific innov origin product addit
propos use prior author step therapi protect class drug
medicar advantag also propos allow greater formulari control
includ broad exclus certain drug commerci plan tactic
use drive lower price manufactur
rebat transpar secretari emphas need provid transpar
rebat fee occur pbm pharmaci payor remov
rebat could dramat chang way drug price
drug price transpar hh releas formal propos requir dtc tv
advertis drug paid medicare/medicaid cost
month suppli usual cours therapi includ list price wac tv
view view broad overhaul unlik happen risk like
debat market caus broad pressur biopharma certain compani
reli minim price increas maintain profit growth other driven
mainli price chang
exhibit price volum summari
specif expect challeng hh part intern refer price
propos predict whether hh would follow plan comment
demo due decemb expect learn whether
hh move forward implement demo taken
lead role adjust new price environ gilead
lower list price key drug limit brand price increas
said still expect price inflat compani though
would expect moder increas rang overal believ biotech biggest
risk chang medicar part given sector high exposur large-molecul
debat alexion celgen gilead face increas multipl compress
either legaci busi face declin sale investor becam concern
upcom potenti cliff expos potenti inflect
exhibit forward price-to-earnings celg
view believ manag neulasta declin biosimilar
way manag rest portfolio thu face cliff said
trade near forward price-to-earnings well sector potenti
candid neg re-rat manag declin legaci busi
event major pipelin event remain limit across space
increment shift major catalyst compar highlight
catalyst could potenti move larg cap smid coverag
exhibit trial readout time potenti stock movement
view major pipelin event across space focu
platform derisk rubiu evelo key genetherapi catalyst
sarepta biomarin pivot data also focu trial gilead
vertex ty seven gilead note impact galapago
phiii data ra also look forward key nash hiv prep
debat repres return posit launch disappoint
spinraza regeneron dupix launch well achiev solid
reimburs highlight strength aimovig
continu launch well biktarvi record hiv trajectori key
launch inflect investor interest respect compani head
key drug launch immunomed alexion like key investor
view see alexion launch launch
key driver stock alexion fast switch could
inflect consensu valu termin multipl re-rat stock
immunomed clean approv quick launch could lead signific upsid
exhibit weekli trx aimovig vs cgrp sinc launch
exhibit monthli trx prauleunt repatha sinc launch
biosimilar matter
debat number biosimilar approv grown
impact market remain modest investor continu wonder
matter
exhibit approv file biosimilar
exhibit biosimilar late stage develop
view two key headwind biosimilar first legal issu relat
patent second lack uptak launch evidenc biosimilar
remicaid former issu major patent case particularli enbrel
ipr case rule favor defend could impact number
product avail launch howev legal develop relat enbrel remain
major focu judg expect rule on-go case
sandoz sandoz prevail could launch immedi potenti drive
investor appear current price tail risk scenario
latter could see approv addit biosimilar neulasta herceptin
avastin launch could greater impact brand thu expect
biosimilar potenti headwind creat key factor
call
larg cap overweight amgen alexion vertex highlight
alexion biomarin see either under-valued base busi pipelin
option drive return specif highlight also
see clear path upsid driven stabl base busi
investor percept alzheim diseas increas vertex see execut
cf busi allow investor fulli valu opportun
see stabl manag busi option driven potenti
key driver
alexion ow pt pdufa date alexion soliri follow-on
approv wide expect launch trajectori open
debat expect product launch rapidli driven dose conveni
everi week versu everi week soliri improv
breakthrough hemolysi robust alexion patient databas expect
manag price preserv valu patient maintain
roughli similar annual price/pati believ fast convers pnh
patient us inflect alexion termin multipl higher
believ current neg base competit biosimilar concern see
robust convers drive alexion higher basi ow
biomarin ow pt see pipelin option drive
specif believ manag deliv posit dataset
hemophilia genetherapi enabl file base factor level
believ success studi achondroplasia also drive
higher see drug potenti opportun would
dramat chang earn power biomarin significantli inflect
exhibit impli upsid larg cap coverag univers base current price
impli upsid current
hcv hiv
compani data thomson reuter morgan stanley research estim valuat methodolog risk associ price target
referenc research report pleas contact client support follow us/canada hong kong latin
altern may contact invest repres morgan stanley research broadway attent research manag new
would expect smid fertil ground idea remain
mani binari event could drive stock coupl
potenti broad smid-cap ralli begin focu convict
name see signific upsid downsid
sarepta ow pt see three key driver first
manag outlin phiii program dmd genetherapi
provid need clariti manag strategi importantli see fast path
market base microdystrophin level could allow registr earli
see upsid derisk genetherapi pipelin
includ limb girdl muscular dystrophi lgmd includ
lgmd bull case assum data meaning would expect
final expect increment manufactur derisk
unlock genetherapi pipelin
immunomed ow pt investor remain concern approv
januari pdufa date expect approv quick launch given
limit treatment option mtnbc see strong launch drive
higher
gw ow gw share primarili driven
progress epidiolex launch dravet syndrom lenox-gastaut
syndrom epidiolex approv june reschedul
septemb launch novemb given epidiolex first fda
approv cannabinoid therapi discomfort therapi
might launch expect drug launch well label indic
account patient expect revenu build begin gain
traction calendar ramp year progress given drug
launch novemb time take secur reimburs
lost sell day due holiday season expect modest sale
calendar time label use becom greater proport sale
phiii data tuber sclerosi complex phiii expect could
help drive earli label use project epidiolex sale sale
track ahead number investor concern regard potenti drug
lessen enabl stock trade upward sharpli view sale fall
neurocrin ow focu shift back ingrezza growth potenti
would expect addit growth tardiv dyskinesia salesforc fulli
run follow expans ingrezza sale
street expect signific declin sequenti quarterli sale
growth mse consensu also see potenti upsid phase
data congenit adren hyperplasia
uw pt remain underweight concern
pivot forward studi could fail believ manag
overestim activ drug mirvetuximab soravtansin
underestim activ chemotherapeut compar arm data
key driver
ironwood uw remain underweight ironwood expect
linzess sale increas pressur competit
difficult put pressur product price beyond linzess believ
ironwood pipelin leav question answer refractori
gerd enter phiii trial howev remain unconvinc
benefit enough make commerci viabl therapi improv
versu placebo appear modest highest phii dose upcom
spin-off co no/sgc/cgmp franchis allow ironwood
focu gi disord unclear point extent move creat
valu sharehold
uw remain underweight concern compet
treatment rcc could reduc cabometyx abil achiev consensu peak
sale although cabo like approv januari pdufa
date sale footprint cover combin rcc
market potenti take conserv stanc expect signific
bolu patient hockey stick cabo sale first coupl quarter
launch beyond potenti approv quarterli earn updat
may see rcc cabo/nivo combin phase data checkmat
exhibit impli upsid smid-cap coverag univers base current price
impli upsid current
migrain neurolog disord
ra cf
neurolog endocrinolog
dmd neuromuscular disord
metabol gastrointestin
renal metabol disord
compani data thomson reuter morgan stanley research estim valuat methodolog risk associ price target
referenc research report pleas contact client support follow us/canada hong kong latin
altern may contact invest repres morgan stanley research broadway attent research manag new
ntgn lower pt pt chang
due move dcf ahead year lower cash balanc sheet
edita medicin lower pt pt chang due
move dcf ahead year lower cash balanc sheet
bio lower pt pt chang
primarili driven lower expect peak sale sickl cell diseas
believ manag make good progress like earli file
plan prior project like high given headwind market
opportun driven pretreat regimen
portola lower pt pt chang due move
dcf ahead year lower cash balanc sheet total remov
bevyxxa model
therapeut umrx lower pt pt chang
due move dcf ahead year less cash balanc sheet
manag spend advanc program expect dilut capit
rais make chang revenu project
 lower pt pt chang due
move dcf ahead year lower cash balanc sheet
chang pipelin revenu project
stock debat
launch trajectori inflect pdufa date
alexion soliri follow-on approv wide
expect launch trajectori open debat expect product
launch rapidli driven dose conveni everi week versu everi
week soliri improv breakthrough hemolysi robust alexion
patient databas expect manag price preserv
valu patient maintain roughli similar annual price/pati
believ fast convers pnh patient us inflect alexion
termin multipl higher believ current neg base
competit biosimilar concern see robust convers drive alexion
higher basi ow thesi
soliri competit becom realiti believ data larg
limit impact soliri competit three main product
consensu focus first brand competit roche/chugai
regeneron develop potenti competit inhibitor
second biosimilar competit brand competit
believ risk brand lower due immun complex
patient face switch product see unlik physician
washout patient switch given risk drug thu see
brand competit matter new patient alexion clear
advantag given commerci infrastructur biosimilar continu
enrol studi expect take year get data thu
see approv earli assum year litig assum
biosimilar could come earliest assum patent settlement
could work
outcom soliri patent updat key patent updat
consensu focus european soliri patent remind
manag pursu strategi formul method use
composit patent soliri us japan europ extend ip
us europ europ alexion grant
formul patent patent oppos oral hear
januari composit patent oral hear februari could
determin grant europ final method use patent await
examin given sizeabl ou revenu base mani investor focus
outcom oral hear europ clear view
patent given nuanc believ like face volatil
around outcom oral hear
much legaci product declin biosimilar consensu forecast
declin across legaci brand potenti impact biosimilar
headwind forecast declin headwind major driver
headwind two biosimilar neulasta brand
consensu model protect brand onpro devic devic
block eros biosimilar consensu estim like
estim headwind would also note face outsiz
risk on-go enbrel litig decis could come would
expect lose case largest product would risk
declin biosimilar year ahead consensu expect would
expect potenti
growth product off-set legaci sale declin consensu
forecast growth new brand major driver includ
repatha aimovig prolia biosimilar thu see new product
offset declin legaci brand maintain busi said
major new growth driver like dramat inflect top-line
growth
manag final pull trigger one
flexibl balanc sheet larg cap biotech free cash flow gener
annual cash balanc sheet look potenti
transform invigor top-line smid-cap name
recent high may abl find key solut attract price
market place believ use balanc sheet key percept
driver
stabil ms base busi base multipl sclerosi busi
face increas competit variou sourc last year
abl maintain market share low singl digit growth ms
market abl grow market growth price
unlik major upsid driver go forward despit competit threat
see underli busi mostli stabl payer formulari
remain open neg impact price limit thu major concern
would shock busi two key headwind come form
potenti ipr largest product tecfidera percept around patent
risk markman hear tecfidera ip district court see risk
low given patent alreadi face ipr markman hear
unlik definit said institut ipr neg markman hear
could impact
much spinraza impact zolgensma risdiplam
spinraza unlik see major impact genetherapi approv
believ incid type patient move spinraza versu larg
prevalence-bas switch year beyond spinraza impact
competit forc said signific growth adult popul
still see potenti spinraza continu signific brand
impact alzheim competit updat
like main driver alzheim percept expect sort
interim futil analysi roch crenezumab significantli differ
mechan aducanumab potenti updat roch
gantenerumab importantli expect updat aducanumab
data expect said would expect move higher
investor posit ahead aducanumab data final expect
updat potenti pivot trial plan manag complet
meet regul start occur octob
key updat revlimid ip continu believ
risk gener revlimid prior launch natco volum control gener
previous written dr reddi lab drl may
polymorph form revlimid may distinct form revlimid
celgen hold patent protect drl file ipr three revlimid
patent cover method use revlimid treat md expir
therefor claim non-infring polymorph patent drl could
gain market access follow expir revlimid composit
patent assum drl ipr patent
success drl polymorph stabl manufactur drl file
ipr august celgen file respons earli decemb
suggest ptab decis whether institut ipr would
avail late februari /earli march drl file ipr
preclud settlement believ suggest settlement immin
also expect trial start addit gener filer manag
highlight recent present trial decis
expect
much off-set near-term launch provid celgen expect launch
bcma car-t car-t therapi liso-cel luspatercept fedratinib
ozanimod manag estim peak non risk-adjust sale
five product key question investor howev
much off-set launch could provid revlimid goe gener
estim five launch contribut aggreg
celgen top line respect one year follow natco
full gener entri estim revlimid revenu fall
repres declin estim declin
project peak revlimid sale year anticip launch
liso-cel luspatercept fedratinib ozanimod gener total
sale well manag estim half
revlimid peak sale result believ five launch anticip
could address portion revlimid revenu lost current base
case natco gener revlimid volum control
launch subsequ full launch case current gener filer
drl abl launch prior howev five launch would
provid much modest near-term off-set potenti lost revlimid revenu
manag abl execut investor heavili doubt
manag abil execut past year follow phiii failur
lower long-term guidanc file delay ozanimod
believ one key set mileston help restor manag
credibl time file ozanimod luspatercept
particularli former base confid manag express
file follow regulatori interact novemb base
commentari earn drug-drug interact studi recent
post clinicaltri gov complet date earli
requir nda resubmiss believ file achiev
also awar issu would delay luspatercept file
manag achiev two mileston schedul believ mani
investor begin regain confid manag abil execut
hiv durabl franchis gilead hcv busi steadili erod hiv
franchis becom key area investor focu three key investor concern
aris frequent regard hiv portfolio atripla truvada patent
expir price pressur competit gsk atripla declin
brand estim ww sale declin
product move toward full gener competit truvada
emtricitabin tdf approv treatment hiv infect well
pre-exposur prophylaxi prep use truvada prep grow
truvada patent expir would open way gener entri
address potenti gener competit prep gilead evalu descovi
emtricitabin taf phiii studi prep agent data expect
success descovi could approv use prep month ahead
truvada gener believ success transit truvada prep
patient descovi could lead upsid consensu project
price concern also arisen recent follow unitedhealthcar
announc reward program aim promot low cost therapi
investor concern valid given hiv drug long view protect
class therapi expect littl near/mid-term impact gilead hiv portfolio
program given hiv treatment driven guidelin prefer taf
base regimen program includ older tdf regimen hiv
larg govern compon discount alreadi substanti
said seem give gsk drug prefer formulari could
indic gsk offer competit price price headwind hiv
would increment neg gilead
nash worth phiii studi work market
reaction nonalcohol steatohepat nash liver condit difficult
diagnos limit treatment option gilead manag estim
patient nash given larg unmet need
condit pose substanti investor interest possibl treatment
nash two phiii readout gilead inhibitor selonsertib
nash data stellar studi patient stage fibrosi
expect data stellar studi patient stage
fibrosi expect manag believ nash
patient stage fibrosi bar efficaci
compani note selonsertib abil demonstr patient
treatment progress experienc diseas regress would
clinic meaning result illustr purpos estim
selonsertib launch grow share current popul could
worth howev given challeng treat nash
proven histor current assign valu
program despit gener interest space believ investor
also await phiii data decid whether valu nash given low
investor expect nash believ risk/reward go stellar
readout skew posit neg readout could pressur
success studi could drive higher investor begin
valu nash sourc pipelin valu
new ceo mean new strategi gilead recent announc daniel oday
current ceo divis becom ceo gilead
effect given roch focu oncolog see hire strong
signal gilead intend continu grow presenc oncolog howev
roch complet acquisit oday tenur may concern
investor look gilead aggress busi
develop gilead veteran gregg alton serv interim ceo
march oday vision gilead like commun
investor mid-lat anticip drastic chang
direct take effect gilead await commentari gilead
manag regard long-term vision suspect involv
growth oncolog busi alongsid hiv franchis life-cycle manag
dupix inflect libtayo launch dupix strong
launch began flatten somewhat howev label expans
asthma younger popul like inflect dupix
current model dupix almost doubl global sale
antibodi libtayo expect sale howev unlik dupix
expect libtayo meaning impact profit
believ estim significantli differ consensu thu believ
dupix would inflect significantli view drive
eylea two major crosscurr eylea
one hand sbla dr could drive sale higher though given
believ harder indic penetr expect rapid adopt
indic hand novarti like file potenti see
approv could provid headwind eylea growth
updat relat could impact investor percept
market overal expect modest growth eylea
investor look pipelin expect increment pipelin
progress regeneron importantli expect key readout
regeneron/teva fasinumab anti-ngf pain drug includ import long-
term safeti studi potenti largest pipelin driver regeneron
though lowest odd success due histori around safeti risk
long-term safeti data import drive percept around potenti
approv expect initi data atop dermat
combin dupix asthma final would expect initi data
fop potenti competitor clementia palovaroten
expect major data
orkambi reimburs standoff resolv point
vertex reach reimburs agreement australia austria denmark
germani ireland itali sweden netherland us manag state
addit revenu growth depend reach reimburs agreement
key countri europ includ uk franc negoti on-going
believ resolut like reach patient advocaci
group continu pressur respect government organ
upsid sale orkambi increment driver vertex key reach
agreement posit vertex abl rapidli launch tripl
tripl combin therapi launch four week interim result
two phiii studi next-gener corrector tripl
combin therapi report addit corrector
demonstr signific improv baselin ad patient
alreadi receiv tezacaftor/ivacaftor result directli compar
interim data two phiii trial second corrector
expect vertex plan submit nda tripl combin
best corrector later follow global regulatori
submiss view efficaci data derisk believ
vertex meet anticip submiss timelin prior cf launch
reach peak sale us month launch file timelin
signific impact time peak sale
els pipelin could drive upsid fda lift clinic hold
autolog gene-edit hematopoiet stem cell therapi
treatment sickl cell diseas repres posit step forward vertex
collabor crispr cover phi/ii trial
europ -thalassemia phi/ii trial us sickl cell diseas
recruit vertex also advanc see significantli
under-valued product look manag detail strateg plan vx-
could unlock valu molecul manag plan
initi phiib dose-rang studi acut pain follow bunionectomi surgeri
work inhibit voltag gate sodium channel peripher
pipelin readout major impact cours
manag expect three key dataset readout first phiii baricitinib atop
dermat data partner lilli second varieti phiii trial gvhd
final phii bladder cancer data inhibitor pemigatinib see
gvhd biggest driver address
pemigatinib believ data increment major upsid driver
final baricitinib expect posit data believ competit
profil molecul lead signific traction indic given
thrombosi risk
gvhd data launch drive upsid short potenti gvhd repres
meaning potenti upsid driver studi readout
see studi treatment-na diseas
import far largest indic could drive million
increment sale said expect major increas jakafi sale
approv late-lin gvhd
prospect hemophilia genetherapi earli file expect
posit data hemophilia genetherapi product
mani investor worri durabl result phi/ii
studi also due believ result good enough satisfi
investor continu view hemophilia peak sale opportun
achondroplasia studi gener posit result hemophilia
expect posit studi key indic also carri potenti
opportun see phii data long-term updat support
catalyst growth outlook
provid catalyst calendar note key mileston compani coverag
univers focu catalyst also provid data competitor
catalyst applic
 ye phii part data expect treat
cmt fshd year end
initi phi data expect neuromuscular
treatment healthi volunt
competitor data earli roxadustat report top-line phiii
efficaci data howev critic safeti mace endpoint disclos
ahead potenti nda investor use data read-through
eptinezumab- alder plan file bla submiss migrain drug
potenti reach market
 result treatment-nav adolesc adult ahu
 pdufa date ultomiri adult pnh
onpattro earli manag plan provid onpattro launch detail
remind compani receiv new patient start form
trajectori expect steadi consist
givosiran earli top-line result phiii envis posit data could lead
potenti nda
inclisiran mid-lat medicin compani report top-line
data orion trial
lumasiran late top-line data illuminate-a trial enrol
complet expect data posit expect file
 follow data investig sponsor phi phii
trial highlight initi patient aga enzym activ octob updat
remain threshold howev long-term stabil remain demonstr
zanubrutinib data comparison zanubrutinib vs ibrutinib wm
zanubrutinib- submit nda fda zanubrutinib patient
 earli file nda relaps form multipl sclerosi
 mid data head-to-head toler studi versu tecfidera
trofiluzole- interim futil analysi pt complet month
 fda respons nda al
rimegep nda submiss acut migrain tablet rapid dissolv
open label lt safeti
valoctocogen roxaparvovec mid- phi/ii long-term updat hemophilia
valoctocogen roxaparvovec mid phiii express data hemophilia
vosoritid -present data phiii trial vosoritid children
achondroplasia year age
lentiglobin initi phiii studi sickl cell diseas scd
ozanimod- nda resubmiss relaps multipl sclerosi rm
oral brincidofovir potenti path file manag look
receiv feedback fda type meet complet anim pox
studi influenc decis
palovaroten regulatori file base phii data episod treatment
fop
palovaroten initi interim analysi phiii move trial
allow snda includ chronic treatment label initi episod
reldesemtiv- phii data expect fortitud studi
reldesemtiv al phiii expect begin expect data
signific catalyst potenti move stock
omecamtiv phiii interim data futil expect
galactic-hf trial omecamtiv mecarbil would expect much upsid
studi pass futil analysi neg outcom would result
dramat pressur share given mani investor see omecamtiv mecarbil
signific driver valuat
clinic data idiopath parkinson diseas
viaskin peanut fda decis bla viaskin peanut children age
 natur histori studi data program
tazemetostat refin registr strategi fda
continu guidanc given earli nda could potenti file
 -initi clinic readout phi studi psoriasi atop
cabozantinib- pdufa date set potenti approv
cabozantinib cabometyx
 rituximab r/r nhl dldcl indol lymphoma
filgotinib- data filgotinib rheumatoid arthriti
filgotinib data phiii studi ra
selonsertib data stellar phiii studi nash
epidoilex continu launch domin investor
convers highlight phiii data opportun gw deliv
pipelin expand thesi
mirvetuximab soravtansin top-lin forward data ovarian cancer
 pdufa mtnbc
gener advair gener launch advair could pressur breo market
share price sandoz hikma file regulatori
convers fda gener version advair mani
compani guid look like sometim
ali final data toler convers
tegsedi- look forward manag provid first sale number
sale metric rel tegsedi launch
waylivra investor debat domin launch
tegsedi phiii readout waylivra fpl next year wait
continu path forward fc
pipelin ioni multipl pipelin drug follow includ
updat rel ionis-httrx ionis-fb-lrx akcea-ttr-lrx
akcea-apo -lrx
regulatori co plan spin ironwood becom
 initi phi phib
 potenti announc data phi studi cancer patient
 late file acceler approv
margituximab data phiii sophia trial posit guidanc
given commerci step manag alreadi progress us commerci
phii data expect maverick studi
mavacamten patient non-obstruct hcm data could
signific de-risk event mavacamten program
data expect patient dilat
cardiomyopathi dcm year end
regulatori lefamulin contepo nda review
underway give opportun manag launch asset
near parallel manag remain focus commerci
product team
initi data expect opdivo combin
initi proof-of-concept phii data expect
adult congenit adren hyperplasia
andexxa chmp opinion request add data latest novemb
 dose escal ar /er metastat breast cancer
eylea- fda decis sbla eylea treat diabet retinopathi
 cohort data phi studi wet
setmelanotid pivot data pomc lepr potenti
approv launch expect
 submit ind phi/ii studi pku
 initi data phi/ii pku studi
 random phiii data postpartum depress
 phase studi preliminari result
golodirsen clinic data essenc regulatori approv
 debat center around abil entinostat aromasin
combin succeed hr breast cancer os endpoint
success interim analysi would allow drug proceed regulatori file
next interim analysi may follow october/novemb
encor pipelin advanc exist studi ovarian cancer data
studi tnbc data
phi/ii data expect cohort studi
over-the-counter around
top-line data phi dose escal oa knee
tripl comb interim analysi two phiii studi test
longer term data expect phib studi vy-aadc
parkinson includ month data patient dose posterior trajectori
dasiglucagon data phiii congenit hyperinsulin may result
potenti regulatori submiss remind emphasi
put glycem paramet primari endpoint note phii data
pediatr sever hypoglycemia may also warrant file
growth fairli steadi
inflect biotech revenu overal revenu flatten primarili
driven decreas gilead revenu project growth remain roughli
mid-singl digit gilead car-t program see provid support
exhibit total revenu top
exhibit total revenu top
gilead uniqu revenu profil due blockbust perform hcv
market gilead revenu remov analysi total revenu
number top biotech compani achiev consist steadi growth
exhibit y/i revenu growth rate
exhibit y/i revenu growth rate
top compani gilead
gilead remov analysi spike also disappear
downward trend revenu growth rate begin
oper margin top biotech steadili improv base
exhibit averag oper margin top biotech
exhibit averag oper margin top biotech gilead
gilead remov analysi signific chang oper
margin also look total ep larg biotech compani see
total ep compani steadili increas exclus
gilead slightli smoothen increas ep effect seem minor
exhibit total ep top biotech
exhibit total ep top biotech gilead
model ep growth increas decreas
exhibit y/i ep growth top top biotech
exhibit y/i ep growth top top biotech
healthcar slow time high
focus later stage market asset half deal asset yet
phiii biopharma activ number increas
 activ still occur late stage
market asset half deal asset yet phiii averag
month perform deal fare better previou
year
histor one-off event high activ larg last
year larger period high activ becom frequent howev
upward trend healthcar time continu show sign
exhibit valu complet us healthcar transact
upward trend overal size healthcar actual number
deal complet remain fairli steadi last year indic
trend toward execut larger deal
exhibit volum complet us healthcar transact
us health complet deal
recent stabil size healthcar transact
proport total transact
exhibit size healthcar transact total deal
us health complet total bn
earli onward continu upward trend healthcar
 deal initi percentag fulli execut current level
observ sinc
exhibit percent healthcar deal complet
us health complet total deal
care offer intens recent climb rapidli peak level recent year
howev recent observ volum revers median
chart display price chang occur revenu
gener compani within coverag
exhibit price chang summari
price-to-earnings basi biotech tick last year all-tim low level compar
rest healthcar forward price-to-earnings current trade around discount
market level seen sinc earli
exhibit price-to-earnings ratio market healthcar
exhibit rel price-to-earnings healthcar biotech market
ev/ebitda basi healthcar pharma trade line
market multipl near low lowest valuat
rel basi ev/ebitda valuat biotech recent revers
time low sector discount continu year thu
compar broader market biotech remain posit break-out
exhibit ev/ebitda market healthcar
exhibit rel ev/ebitda healthcar biotech market
dramat improv yield last decad yield
current premium pharma healthcar overal market sector
abl larg hold out-performance sinc may late-
cycl trend manag team move invest new product cycl posit
biotech well invest cycl
exhibit yield market healthcar pharma
basi investor paid premium biotech growth rel
pharma biotech valu remain fairli steadi sinc occasion
volatil pharma valuat steadi posit
exhibit median valu pharma
biotech valuat highli depend larg termin valu driver
result biotech valuat highli sensit chang discount rate us
equiti market whole neg exposur steepen yield curv accord
global equiti strategi team increas yield curv slope associ
expect market return continu expect rate increas
highlight known clear headwind
exhibit pharma yield curv level sensit
ipo volum continu trend upward current approach time high
level follow-on hit time high sinc break previou high set
exhibit histor number biotech ipo follow-on
deal dollar amount continu trend upward break time high note
ipo particular record break rais like make current level reproduc
exhibit valu biotech ipo follow-on
year year return biotech ipo diminish ipo
basket first neg return last longer month
ipo basket remain posit part interestingli
ipo basket come significantli last year outpac
exhibit return biotech ipo
thomson reuter morgan stanley research note delist compani exclud earli spike return ipo
relat stock price perform
ipo step up remain stabl observ slight increas
premium head end
exhibit ipo step-up healthcar crossov round
summar market trend market share evolut key market
us market gcsf therapi decreas year-over-year
bit uptick base im prescript data ytd predict
signific decreas
exhibit gcsf y/i market size decreas
exhibit gcsf market share evolut
im data indic size us esa market decreas sinc
follow flat growth epogen lost signific share sinc
aranesp procrit bit uptick year note im data
track roch mircera present signific competit epogen
freseniu medic north america oper larg number outpati
dialysi center us
exhibit esa y/i market growth/decreas
exhibit esa market share evolut
im data indic inject anti-tnf market grown steadili year-over-
year estim growth expect im data indic
enbrel gradual lost share humira cimzia maintain
consist share us prescript
exhibit anti-tnf y/i market growth/decreas
exhibit anti-tnf market share evolut
im prescript data indic hiv market sharp increas revers
slight growth observ contract
base prescript gilead share us hiv market grown steadili
prescript share evolut gilead hiv
therapi provid
exhibit hiv y/i market growth/decreas
exhibit market share prescript gilead hiv therapi
approv sovaldi harvoni substanti increas size hcv daa
market therapeut recent lose share epclusa
mavyret im prescript trend also demonstr sovaldi harvoni
rapid uptak provid bolu hcv market moder consist
exhibit hcv y/i market growth/decreas
exhibit hcv prescript market share evolut daa market
im prescript data indic ms market consist grown
histor recent contract expect lessen
compar maintain prescript share
exhibit ms y/i market growth
exhibit prescript share evolut select ms therapi
gener outperform broader market ytd btk
vs howev out-performance half out-performance
observ addit biotech sector perform line pharma
gener healthcar wherea btk significantli outperform
drg iyh factor weigh biotech sentiment
constant polit nois regard measur curb drug price lower level
 sector vs investor expect go year
exhibit perform drg vs btk gener healthcar ytd
exhibit perform iyh vs btk ytd
exhibit perform btk vs ytd
better understand foreign exchang movement effect mani compani
coverag univers analyz trend dollar versu euro yen
dollar fell compar euro late usd climb
slowli mid-year remain stabl sinc compar japanes yen
usd show weak begin year remain rel stabl
latter half
full phase ii compani competitor readout
highlight phii phiii catalyst occur tabl
broken trial compani darker color trial
repres compani coverag univers lighter color
trial repres competitor drug trial subject chang without
primari complet date
advanc solid tumor non-hodgkin lymphoma nhl
advanc solid tumor non-hodgkin lymphoma nhl
compani
pre-exposur prophylaxi infect
non-alcohol fatti liver diseas women pco
compani
spy-phi
recurr metastat breast cancer
compani
local advanc metastat solid tumor
er ar breast cancer
recurr metastat breast cancer
metastat breast cancer skin cancer
advanc recurr breast cancer
persist recurr cutan t-cell lymphoma
advanc solid tumor non-hodgkin lymphoma nhl
tsebt
non-alcohol fatti liver diseas women pco
hcp administr
compani
cediranib olaparib
local advanc metastat solid tumor
platinum-sensit ovarian cancer first relaps
pt deriv dcf use
discount rate assum po md beta-th
addit assum po first line md non-
transfus depend beta-th mf respect
posit data mf non-transfus depend beta-th bull case
rais probabl success po program
base case
luspatercept launch reach peak ww revenu
first two indic base case assumpt describ price
target methodolog
luspatercept get approv bear case scenario assum
acceleron product abl advanc trade cash value-per-share
equal-weight rate base
expect limit upsid near-term
posit luspatercept
assum high probabl approv
next set data
luspatercept phase data betal-th
top-line luspatercept phase data mf
top-line phase part data
top-line phase part data
data non-transfus depend beta-th
top-line sotatercept data phase
pulsar studi patient pah
risk achiev price
upsid risk better-than-expect mf
downsid risk neg mf fshd data
vadadustat drive akebia share
vadadustat drive akebia share
pt deriv dcf use discount rate
termin growth rate beyond valu akebia nephrolog
vadadustat exce expect allow therapi take addit share
epo regimen appli risk adjust
vadadustat launch drug profil allow success howev
ampl risk remain program lead risk adjust
vadadustat fail merger fall compani valu cash
equal-weight ahead phiii
major cardiac event mace data
see vadadustat therapi
benefit allow remov black
box respect cardiovascular event
might necessari success versu
roxadustat lead time
roxadustat mace readout earli could
benefit hif class posit
howev even posit therapi
year ahead vadadustat could
challeng reach market
infrastructur auryxia need show us
recent merger keryx
auryxia join vadadustat compani
ckd aresen auryxia
underperform sinc approv
hypophosphatemia though drug
recent expand label includ iron
defici anemia need see
drug perform gain confid
potenti expect updat model
keryx merger earn
main valuat driver
perceiv clinic regulatori risk
vadadustat ckd dialysi set
risk achiev price
vadadustat demonstr lack efficaci
signific safeti issu emerg lead
program discontinu
roxadustat phase studi ckd
signific differenti vs vadadustat
side raxadustat produc
question data lead increas
doubt regard class
merger keryx might complet
akebia might need rais addit fund
issu equiti
cost expens
product revenues/royalti
cash equival
prepaid expens current asset
properti equip net
defer revenu net current portion
accumul comprehens incom loss
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
prepaid expens asset
accru expens liabil
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
chang equival
equival begin year
equival end year
market secur end year
pt deriv dcf use
discount rate given posit phase data assum
probabl success po howev fourth cgrp
market assum peak market share episod migrain
chronic migrain impli peak unadjust sale almost
stronger uptak follow success cgrp bull case assum
faster ramp greater peak market share episod migrain
chronic migrain result stronger-than-expect launch
cgrp
eptinezumab approv base case assumpt describ
price target methodolog
eptinezumab fail alder unabl obtain approv eptinezumab aldr
trade cash value-per-share
underweight thesi base
eptinezumab like fourth cgrp
although eptinezumab fast onset
action view efficaci cgrp
howev eptinezumab less conveni
administ iv infus cgrp
inject subcutan addit
least one oral cgrp could approv
episod migrain within coupl year
believ physician prescrib
eptinezumab sever patient
risk achiev price
risk upsid alder announc
new product candid rel
advanc indic larg market
approv addit cgrp
better-than-expect sale eptinezumab
risk downsid fda
accept alder file launch
cgrp significantli street
expect new safeti signal detect
cgrp believ
clinic data strensiq kanuma soliri label expans nmo drive
strensiq kanuma soliri label expans nmo drive
overweight believ
current valuat impli manag
unabl grow busi
overlook share shift potenti
even conserv scenario
assum achiev solid
profil assum either market share
price pressur year
assum strensiq achiev
meaning sale see modest sale
key revenu driver model
continu ahu pnh sale growth
franchis coupl growth
soliri mg success share shift
model nmo sale start
risk achiev price
soliri pnh ahu mg growth could fail
meet expect soliri nmo may
launch strensiq and/or kanuma could fail
meet expect could
fail leav soliri unprotect
competit could bad
behaviour identifi commerci
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model pnh sale ahu sale mg sale nmo sale strensiq
sale kanuma sale incorpor cash cost stock
diagnost algorithm drive sustain pnh ahu mg penetr soliri
approv nmo succe signific share
convers bull case assum soliri becom standard care pnh
ahu nmo mg pnh sale ww
ahu sale peak assum strensiq kanuma
continu launch sale respect
soliri meaning growth pnh ahu gmg succe
modest share convers base case assum on-going geograph
expans continu drive soliri penetr pnh peak sale
ahu also assum strensiq peak sale
kanuma see soliri longev incorpor competit
soliri fail nmo strensiq kanuma achiev minim sale soliri face
signific competit bear case assum soliri fail gain label
expans soliri face signific headwind biosimilar
proprietari competit diversif strensiq kanuma minim
onpattro sale advanc pipelin drive valu
onpattro sale advanc pipelin drive valu
pt deriv dcf use discount rate
termin growth rate beyond valu alnylam advanc
onpattro highli success givosiran achiev strong sale fitusiran
launch bull scenario assum onpattro highli success
treatment hattr-pn givosiran launch sell well appli modest
pipelin valu drug
onpattro drive valu givosiran launch assum strong launch
onpattro also assum givosiran approv aip appli
modest pipelin valu drug
equal-weight alnylam
believ success launch onpattro
approv givosiran alreadi
price share
view alnylam rnai platform
high potenti valu consid
rnai simpler demonstr preclin
proof concept technolog
alnylam larg pipelin beyond ttr
therapi offer potenti
ramp onpattro well
clinical/regulatori updat givosiran
lumasiran fitusiran inclisiran drive
risk achiev price
pipelin success failur
proprietari rnai therapi could lead
substanti chang share valu
posit neg safeti and/or
efficaci data therapeut
program develop
clinic data competit program
suggest advantag disadvantag
drug alnylam develop portfolio
million per share basi indic
net revenu collabor
cost expens
product revenu royalti
million per share basi indic
equival
invest equiti secur regulu therapeut inc
prepaid expens current asset
properti equip net
defer revenu net current portion
total liabil sharehold equiti
million per share basi indic
adjust reconcil net loss net cash use oper activ
depreci amort
chang oper asset liabil
bill unbil collabor receiv
pre-paid expens asset
accru expens
net cash provid use oper activ
purchas properti plant equip
purchas market secur
sale matur market secur
increas reduct restrict cash
payment asset acquisit
net cash use invest activ
proce exercis stock option equiti
proce issuanc common stock
proce issuanc debt
net cash provid financ activ
chang cash cash equival
cash equival begin year
cash equival end year
market secur end year
biosimilar competit pipelin contribut drive risk-reward
biosimilar competit
overweight amgen believ
upsid pipelin recent
launch help reduc long-term risk
compani current base busi face
signific in-organ opportun growth
stabl base even biosimilar
believ protect key franchis
biosimilar competit near-term
long-term forecast gradual share
shift biosimilar versu cliff key
product neulasta enbrel
project period
divers pipelin begin
appreci gener posit
late-stag data key pipelin compound
earli aimovig launch migrain
appear encourag also
develop portfolio biosimilar
molecul believ take share
encourag outcom data also
report repatha believ
data drive fundament shift repatha
uptak beyond
launch perform aimovig
erenumab migrain approv launch
biosimilar molecul
advanc early-stag
biosimilar entrant key legaci product
enbrel neulasta enbrel price power
risk achiev price
failur late-stag pipelin
lack margin expans
deriv pt discount cash flow dcf analysi
use wacc termin growth rate post
bear case main revenu driver model
eros base busi due biosimilar launch repatha
matur late-stag pipelin
lower biosimilar impact coupl outsiz revenu phase
pipelin assum pipelin sale romosozumab
biosimilar erenumab repatha sale modest
line penetr kyproli sale enbrel long-
term patent hold biosimliar enter market minim
impact biosimilar expos product biosimilar neulasta take
total neulasta share
us biosimilar impact similar trend europ modest result
phase pipelin assum pipelin sale
biosimilar erenumab repatha sale
line penetr kyproli relapsed/refractori market
global sale enbrel biosimilar begin take share
modest impact biosimilar expos product biosimilar neulasta take
total neulasta share
signific biosimilar impact pipelin contribut except repatha
assum repatha sale line penetr
kyproli relapsed/refractori market sale enbrel
biosimilar enter market take signific share brand
enbrel notabl impact biosimilar expos product biosimilar
neulasta take total neulasta share assum sg
save lt sg sale
epogen us may
equival
current portion defer revenu
current portion convert note
defer revenu net current
common stock apic
total liabil equiti
write-off in-process research develop
tax benefit relat employe stock option
increas decreas defer revenu
chang oper asset liabil
net cash provid use oper activ
purchas pp
net cash use invest activ
net proce issuanc common stock upon
exercis eso connect esop
tax benefit relat employe stock option
chang convert
net cash provid financ activ
chang cash
begin year
end year
market secur end year
attract lentivir gene therapi platform drive valu
attract lentivir gene therapi platform drive valu
gene therapi compani
develop lentivir therapi lysosom
compani lead therapi
fabri diseas alreadi clinic data
human suggest therapi
could potenti cur derisk
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model risk adjust sale fabri diseas gaucher
diseas market well underli gene therapi platform valu
steeper ramp fabri gaucher scenario assum first revenu avr-rd-
reach peak appli risk adjust
launch reach peak risk
adjust includ modest peak adjust sale pomp cystinosi
fabri gaucher drive valu scenario assum first revenu
reach peak appli risk adjust avr-
launch reach peak risk
program fail valu cash
establish market alreadi identifi
popul also regulatori path well
establish make diseas less riski
rare diseas opportun
program earliest
potenti approv primari driver
valuat gaucher
diseas also key driver
risk achiev price
poor clinic data neg impact
street view specif pipelin
product gene therapi whole would
detriment share valu
lsd establish market
standard care product
like higher bar success
compet technolog gene
competit risk long haul
cost expens
good sold
net incom common sharehold
prepaid expens current asset
properti equip net
defer revenu net current p\ortion
total liabil sharehold equiti
flow oper activ
adjust reconcil net loss net use oper activ
chang oper asset liabil
prepaid expens asset
net provid use oper activ
flow invest activ
purchas properti plant equip
purchas market secur
sale matur market secur
net use invest activ
flow financ activ
proce exercis stock option equiti
proce issuanc common stock
effect exchang rate
chang equival
equival begin year
equival end year
market secur end year
success develop i/o combin therapi access ex-china market
success develop i/o combin therapi access ex-china market
execut local china market drive risk/reward
execut local china market drive risk/reward
overweight beigen preclin
earli clinic data indic beigen four
parp inhibitor could
present differenti profil varieti
beigen uniqu posit develop
i/o combin therapi given own
compon drug preclin studi in-
hous combin promis date
choos develop drug china
beigen elig pursu potenti
acceler path approv
multi-national competitor could provid
year head start access chines
uptak oncolog drug china
indic strong demand healthcar
insur reform grow market
time believ chines market
could serv valuat backstop
deal celgen valid
beigen discoveri platform strengthen
compani cash posit provid
commerci infrastructur facilit
eventu commerci beigen
product candid china
updat chines penetr
btk parp program
monotherapi combin platform
updat pathway
risk achiev price
on-going clinic trial particularli
inabl demonstr superior
compet compound later-stag
develop market
regulatori chang china
pt deriv dcf use discount rate
termin growth rate beyond valu beigen four clinic
stage product candid recent acquir oper china
beigen four product candid achiev strong uptak china
ex-china market driven differenti profil uniqu
combin therapi product sale reach
beigen
earn royalti ex-china
sale respect revlimid abraxan vidaza china gener
annual sale beigen earn aggreg
develop regulatori commerci mileston payment
collabor celgen
beigen abl launch four current clinic stage product
candid modest uptak within outsid china product sale
estim
beigen earn
royalti ex-china sale respect
revlimid abraxan vidaza china gener annual sale
beigen earn aggreg develop regulatori
commerci mileston payment collabor
failur develop launch molecul combin therapi china
develop posit access
spinraza tecfidera ocrevu pipelin drive risk-reward
spinraza tecfidera ocrevu pipelin drive risk-reward
overweight biogen see
multipl sclerosi sale trend
consensu threat like ocrevu less
impact expect new
launch spinraza better
expect see long-term upsid
differenti pipelin alzheim
lead solid data aducanumab
establish proof concept allow us
valu program continu see
 engin strong lt driver
pipelin readout
risk achiev price
slower expect launch
loss gener copaxon robust
driver tecfidera spinraza ocrevu pipelin specif
aducanumab alzheim diseas
tecfidera market share limit impact biosimilar signific
margin expans lower discount pipelin asset assum
peak tecfidera sale expir
plegridy/avonex sale impact rituxan/gazyva biosimilar
bp margin expans versu base case
pipelin base busi valuat
impact valu pipelin assum peak
tecfidera sale declin plegridy/avonex sale
biosimilar rituxan impact start ocrelizumab robust use
ppm take modest share tysabri line rrm
pipelin base busi valuat
impact pipelin assum global tecfidera sale
loss patent protect declin plegridy/avonex
sale part due biosimilar avonex launch
biosimilar rituxan impact start bp margin contract
base case ocrelizumab take overal rrm share robust
ppm penetr per share pipelin
rimegep competitor migrain data glutam platform valid drive
rimegep competitor migrain data glutam platform valid drive
deriv pt discount cash flow dcf analysi
assum wacc termin growth rate post
main revenu driver model rimegep
episod migrain lesser extent glutam platform
robust rimegep uptak episod migrain commerci
chronic migrain strong share addit neurolog indic
glutam net product sale driven sale
rimegep aggreg cgrp
platform ex-u sale aggreg sale trigriluzol bhv-
 ex-u
strong share rimegep episod migrain modest share
addit neurolog indic glutam platform net
product sale driven sale rimegep
ex-u commerci commerci chronic
migrain aggreg sale trigriluzol
 commerci ex-u
pipelin failur rimegep glutam platform molecul fail
develop process compani trade cash value-per-share
overweight biohaven lead product
unmet need acut treatment
migrain phiii data suggest product
could differenti emerg
competitor particularli safeti
signific pipelin driver trigriluzol bhv-
gener encourag
data trigriluzol achiev
statist signific result phii/iii
spinocerebellar aia sca program result
drug inabl differenti
placebo seem trial/ind specif
current see limit read
rimegep regulatori catalyst
risk achiev price
poor percept phiii efficaci vs phii
result limit commerci uptak
poor safety/efficaci data
base busi brineura vosoritid bmn drive valu
base busi brineura vosoritid bmn drive valu
aldurazym pipelin vosoritid bmn greatest
extra strength pipelin assum expect growth base
busi drug pipelin vosoritid bmn becom even larger
driver valu
pipelin contribut assum base busi perform well come
year also pegvalias approv trifecta vosoritid bmn
 bmn launch model probabl success
vosoritid bmn bmn
pipelin current approv drug assum drug
pipelin unabl gener satisfactori result gain market approv
bear scenario
leader orphan opportun biomarin
uniqu player core
compet orphan drug set apart
larg cap emphas market
target larger popul
strength base busi establish
valu base busi vimizin naglazym
kuvan aldurzym contribut
revenu given natur market outsid
competit unlik allow base
busi creat valuat backstop
deep pipelin offer plenti
opportun upsid biomarin deep
wide product pipelin multipl drug
potenti launch end
vosoritid bmn possibl
blockbust contribut upsid
pipelin opportun near-term focu
investor focu pipelin
opportun nearer-term launch
pegvalias pku well potenti
blockbust vosoritid achondroplasia
bmn gene therapi treatment
find patient drive sale
base busi base busi drug
still grow recent launch
vimizim still leg drive sale
biomarin abil steadili find new patient
grow revenu opportun
bmn hemophilia gene therapi
bmn could signific impact
valuat matur data becom
risk achiev price
neg updat key pipelin drug
highlight safeti efficaci risk
bmn failur phase
focu orphan asset price could
impact investor view base busi
pipelin upsid particularli impact
termin valu busi
expens manag particular
meet year oper margin target
car-t bcma sickl cell beta-thalassemia gene therapi drive risk/reward
car-t bcma sickl cell beta-thalassemia gene therapi drive risk/reward
signific sickl cell uptak bcma car-t high share relaps set
modest beta-thalassemia penetr assum larg portion
elig scd patient receiv gene therapi signific portion
new incid popul receiv therapi beta-thalassemia assum
row penetr assum strong launch penetr
front line patient
uptak beta-thalassemia us/eu strong bcma car-t uptak
line moder sickl cell penetr scd project peak ww sale
assum oral competit baselin factor organ damag
stroke etc limit uptak gene therapi beta-thalassemia assum
penetr develop market scd price
factor late line us patient drive peak sale
lentiglobin fail make market assum scd
beta thal make market model cash-bas valu assum
launch
equal-weight
compani progress sickl cell diseas
reflect valuat see car-t
bcma program main upsid
believ initi data repres
proof-of-concept allow us valu
penetr sickl cell market
penetr beta-thalassemia
see initi bcma car-t data
strong highli valu segment
peak sale assum
maintain major share
competit compani
addit car-t data durabl
data earlier line therapi
addit data follow-up
lentiglobin beta-th scd studi
new clinic program either gene
therapi car-t gene edit
risk achiev price
potenti efficaci safeti concern
would inhibit manag team
bring market add
indic earlier line
efficaci lentiglobin given
limit number patient potenti
variabl patient engraft diseas
sever patient respons
safeti lentiglobin given lack
long-term follow-up limit patient
revlimid growth patent expir pipelin execut risk otezla drive risk-
revlimid growth patent expir pipelin execut risk otezla drive risk-
outsiz market share line durat month revlimid
strong otezla full realiz pipelin asset assum
hematolog sale abraxan sale
otezla sale ozanimod sale rrm uc
juno car-t sale bcma car-t
revlimid otezla sale near guidanc commerci success
ozanimod low-end guidanc assum
hematolog sale abraxan sale
otezla sale ozanimod sale rrm uc
juno car-t sale bcma car-t
slow revlimid eu growth slow otezla launch minim pipelin success
assum hematolog sale abraxan sale
otezla sale
equal-weight celgen
continu believ threat gener
revlimid prior consensu expect
persist pipelin asset face
high bar believ recent pull back
celg brought stock level
better reflect view threat base
busi pipelin
revlimid believ revlimid continu
grow penetr continu use
set modestli current rate
us signific degre europ
gener revlimid arriv
otezla believ otezla trajectori
continu progress gradual
acknowledg agent larg market
could ultim lead sizabl sale
clearli signific upsid sale could
caus us re-evaluate ew thesi
ozanimod model peak sale
believ signific sale multipl
sclerosi difficult given potenti
gener gilenya near time launch
uc believ peak sale
achiev acknowledg
domin agent achiev
sale biosimilar tnf present risk
main driver revlimid
otezla ozanimod lesser extent
risk achiev price
unexpect upsid pipelin
earli patent expir revlimid
sale manag guidanc
especi otezla
failur limit success pipelin
program includ car-t partnership
bio juno solid tumor
studi ozanimod
dilut share ep modelwar
equival
asset held sale
properti equip net
invest affili compani
current portion defer revenu
liabil dispos group
defer revenu net current
long-term debt net discount
common stock treasuri cost
accumul comprehens incom
total liabil sharehold equiti
alloc pre-paid royalti
provis benefit account receiv allow
impair acquir in-process research develop
chang valu conting consider
acquir in-process research develop
equiti loss affili compani
share issu employe benefit plan
unreal chang valu foreign currenc forward contract
realiz market secur
total chang work capit
net cash provid use oper activ
proce sale market secur avail sale
purchas market secur avail sale
net cash use acquisit
proce sale non-cor asset net
invest affili compani
purchas invest secur
net cash use invest activ
proce issuanc long-term debt
purchas treasuri stock
net proce short-term borrow
payment conting consider
net proce exercis common stock option warrant
excess tax benefit share-bas compens arrang
net cash provid financ activ
chang foreign exchang rate
chang cash cash equival
cash equival begin year
cash equival end year
market secur end year
deriv pt discount cash flow analysi use
wacc termin growth rate
brincidofovir success share hct sot assum strong launch
adv treatment multi-vir prevent sot penetr begin
brincidofovir approv slower growth assum adv penetr
launch year penetr prevent sot
penetr reach
brincidofovir get approv achiev minim success assum modest
penetr across hct treatment/prevent sot
underweight
brincidofovir unabl achiev
posit result two phiii trial
manag forg new path forward
upcom adapt trial treat adv
mvp-ped studi multi-vir
prevent new approach remain
riski mani addit hurdl clear
brincidofovir reach market
brincidofovir show solid earli data
emptiv standard care fail phiii
suppress trial phiii advis trial
main revenu driver model
launch brincidofovir adv treatment
multi-vir prevent
risk achiev price
brincidofovir unabl reproduc phii data
show efficaci upcom adapt
new trial lag higher expect
cost lead financ gap
toxic issu primarili gi
contribut phiii suppress failur emerg
futur trial
fop launch assum launch palovaroten fop
mo steep ramp annual price fop risk adjust
mo
fop launch assum launch palovaroten fop
mo gradual ramp annual price fop risk adjust
appli mo
palovaroten fail compani valu cash
palovaroten could highli profit
therapi treatment ultra rare
diseas fop mo avail
treatment palovaroten
promis clinic
phii data safeti databas de-risk
program data phii program
demonstr potenti efficaci therapi
fop extens patient safeti
databas former molecul owner roch
take one key risk tabl phii data
fop combin anim data suggest
potenti success mo
regulatori agenc board recent
meet regulatori agenc suggest
fda ema board
trial palovaroten fop start later
year phii/iii trial mo also
potenti pivot would begin
later year
clementia share driven
develop palovaroten
treatment rare bone diseas includ
multipl osteochondroma mo
risk achiev price
question efficaci safeti data
neg clinical/regulatori updat
palovaroten program fop
mo could place pressur clementia
fop mo avail
treatment option littl track record
assess market potenti
therapeut address disord
competitor regeneron examin
activin target antibodi treat fop
clinic nois respect candid
omecamtiv mecarbil reldesemtiv drive risk/reward
omecamtiv mecarbil reldesemtiv drive risk/reward
pt deriv dcf use
sale peak unadjust ww reldesemtiv sale
sma al probability-adjust revenu use
po om reldesemtiv al reldesemtiv
sma
higher probabl success reldesemtiv bull case assum
higher probabl success po al follow success reldesemtiv
phase data po sma start phase trial
om reldesemtiv commerci begin base case
assumpt describ price target methodolog
product candid fail unabl advanc product
candid trade cash value-per-share
equal-weight thesi base
omecamtiv mecarbil driver
valuat de-risk phase data
expect
cautiou reldesemtiv sma
given recent phase data sma
despit potenti upsid al
uncertainti whether dose high
reldesemtiv phase data al
omecamtiv mecarbil phase data hf
reldesemtiv phase data sma mid-
risk achiev price
upsid risk includ addit data new
product candid announc better-
than-expect reldesemtiv phase data
reldesemtiv phase data al
epicutan peanut egg milk allergi treatment drive risk/reward
milk allergi treatment drive risk/reward
deriv pt dcf base forecast dbv peanut
milk egg allergi product candid viaskin peanut viaskin milk
viaskin egg use discount rate termin
growth rate see allergi preval increas grow
popul also model effect competit
modest share viaskin peanut commerci viaskin milk
viaskin egg viaskin peanut achiev moder uptak high low sever
peanut allergi patient us eu global sale
us eu viaskin milk viaskin egg launch
respect obtain minim share achiev
global sale
modest uptak viaskin peanut commerci viaskin milk
viaskin egg viaskin peanut achiev global sale
us eu contribut viaskin milk viaskin
minim success viaskin peanut commerci viaskin milk
viaskin egg minim penetr viaskin peanut high-sever
childhood peanut allergi patient popul achiev global sale
equal-weight
gener mix phiii top line profil
drug still seem approv
believ mix dataset make viaskin
peanut approv less certain
compromis viaskin peanut abil
compet potenti competit
viaskin milk viaskin egg repres
potenti upsid driver target
market high unmet need howev
given earli natur program
mix late-stag result viaskin peanut
egg milk program factor
bull case modest uptak
full data present phiii
safety/efficaci pepit studi viaskin
regulatori feedback pathway
find dbv preclin work
viaskin egg outlin clinic
develop plan preclin work
risk achiev price
lengthi unexpect delay
viaskin peanut reach market
greater expect competit threat
aimmun peanut allergi
program al alzheim parkinson bbb platform drive risk/reward
program al alzheim parkinson bbb platform drive risk/reward
pt base dcf base case forecast
parkinson al alzheim bbb platform
discount rate assum termin growth cash
greater alzheim market share success idiopath parkinson
bull case assum market share al market share
alzheim share total parkinson popul alzheim
risk-adjust us peak sale program
program bbb program repres total peak
risk-adjust success alzheim good probabl success
mutat valu bbb program base case assum
market share al market share alzheim share
mutat parkinson us peak risk-adjust sale
program program bbb program repres
total peak revenu
alzheim success mutat parkinson valu bbb
program approv al alzheim approv
parkinson al program gener peak revenu
program gener peak revenu bbb program repres
peak revenu
overweight thesi base
confid manag abil
inflect product histor
difficult treat area neurosci
believ manag right
process inflect success use
genet target biomark target
engag parallel invest
improv success initi target
repres initi yardstick
opportun greatli expand treatment
engag
engag data
patient program
potenti evid activ
initi preclin clinic data
demonstr util bbb
risk achiev price
preclin clinic safeti signal
program
inabl advanc
program clinic test due poor
efficaci concern safeti signal
failur bbb program greater
success competitor similar program
demonstr safe administr human ip resolut success
demonstr safe administr human ip resolut success
pt deriv dcf use discount rate
edita abl develop commerci therapi receiv widespread
uptak therapi launch us eu treat
cure address popul command premium
price gener peak ww sale edita also abl
realiz sale addit therapi car-t applic
non-malign hematolog dmd cf
therapi prove success addit therapi obtain modest
success therapi launch us eu treat
cure address popul gener peak ww
sale edita abl develop success therapi car-
hematolog dmd cf achiev sale
pipelin program fail edita abl commerci therapi
result valuat cash share
equal-weight
crispr gene edit platform
derisk oper standpoint
gear toward numer diseas
target howev deliveri long-term
safeti administ clinic relev
dose human need proven
edita system modular approach
may allow differenti
first diseas target
inherit retin dystrophi lower initi
risk prove gene edit work
human eye immun privileg
provid small contain area
suffici quantiti vector
overal see signific long-term
potenti edita remain equal-weight
initi therapi derisk clinic
progress program
program clinic
hematolog diseas genet diseas
lung liver
risk achiev price
ip outcom limit edita freedom
develop risk associ earli
natur pipelin timelin long
competitor could influenc investor
percept stock
pt deriv dcf use discount rate
termin growth pt deriv dcf use
discount rate termin growth rate beyond valu
clinic hold lift tazemetostat approv ramp well assum
tazemetostat launch es fl dlbcl
appli risk adjust dlbcl respect assum partial clinic
hold lift well steeper overal ramp
tazemetostat launch risk assum tazemetostat launch
es fl dlbcl appli risk adjust
fl dlbcl respect lift clinic hold
program fail compani valu cash
ew epizym believ
partial clinic hold tazemetostat cloud
view time though expect
hold like lift presenc prevent
compani progress fl key
es small indic big proof
concept compani appear track
submit indic small
approv would valid
probabl success larger opportun
follicular lymphoma primari driver
valu given earli data fl
approv indic
process defin registr path
tazemetostat monotherapi
indic howev given clinic hold
time natur registr
primari driver
tazemetostat treatment fl
risk achiev price
safeti issu continu challeng
compani prevent develop
tazemetostat
might suffici efficaci
compet current treatment
collabor fail result meaning
probabl success monoclon microbi therapi drive risk/reward
probabl success monoclon microbi therapi drive risk/reward
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model evelo lead monoclon microbi product candid
atop dermat psoriasi
signific share atop dermat psoriasi evelo inflamm
focus monoclon microbi launch atop dermat
psoriasi atop dermat evelo product gain share peak
patient control topic treatment psoriasi evelo obtain
share peak patient biolog oral respect assum
probabl success po estim peak po adjust revenu
modest share atop dermat psoriasi evelo product candid gain
share peak atop dermat patient control
topic treatment gain share peak psoriasi
patient biolog oral respect assum po estim
peak po adjust revenu
program fail valu compani cash
treat system condit via gut-
bodi network nascent field evelo
signific clinic literatur recent
year support premis gut-bodi
network preclin data gener
date evelo lead product candid
inflamm oncolog encourag
scalabl sever potenti target
therapeut inher safe
deriv gut
initi clinic data
psoriasi atop dermat
respect
multipl oncolog studi
begin
risk achiev price
earli setback microbiom
focus compani may weigh investor
safeti efficaci lead develop
program remain unclear
therefor risk initi clinic readout
investor may write entir evelo
platform earli data readout
pt deriv dcf use discount
rate model peak us market share translat
unadjust peak sale risk-adjust use
probabl success po rcc assum peak us market share
translat peak sale
greater peak market share rcc bull case assum
peak us market share translat peak sale
assum po januari approv addit assum
peak us market share rcc maintain share
translat peak sale rcc
cabozantinib launch base case assumpt
describ price target methodolog
lower long-term market share rcc greater-than-expect
share rcc
underweight thesi base
belief cabozantinib face difficulti
increas long-term adopt rcc
numer compet drug
develop indic
think tyrosin kinas inhibitor
continu face pressur io agent
believ sale growth slower
expect
data rcc
potenti approv cabozantinib
risk achiev price
sale cabometyx rcc beat street
growth cabometyx sale rcc beat
earli sale exceed expect
combin studi cabozantinib
trial earlier stage asset posit
expect
advanc clinic
announc addit data
support advanc cabozantinib
indic beyond rcc
updat antibodi drive risk/reward
updat antibodi drive risk/reward
pt base dcf use discount rate project free
cash flow base termin valu
onward use termin growth rate project revenu
lead product candid dlbcl ovarian cancer colorect
cancer risk-adjust basi
strong uptak dlbcl solid tumor see strong uptak
use broadli across r/r front line dlbcl set
base case gener peak risk-adjust sale also
gain greater share colorect cancer ovarian cancer gener peak risk-
adjust sale
modest uptak dlbcl solid tumor dlbcl gener
risk-adjust revenu
assign po probabl success dlbcl gener
risk-adjust solid tumor revenu colorect cancer ovarian cancer
assign po solid tumor
fail liquid solid tumor fail develop stage
across indic result forti seven trade cash value-per-share
overweight forti seven
believ earli clinic data gener
antibodi highli encourag across
oncolog indic could first-in-
class therapi new categori checkpoint
data gener date indic
potenti strong singl agent activ
well activ could complementari
anti-canc agent
phi monotherapi data solid tumor
phi/ii combin therapi data r/r
nhl earli
phi/ii combin therapi data
data atezolizumab
azacitidin aml
risk achiev price
poor efficaci and/or safeti data lead
stronger expect data
filgotinib ra ibd pipelin asset drive risk/reward
filgotinib ra ibd pipelin asset drive risk/reward
deriv pt discount cash flow analysi use
wacc cash flow forecast expir
filgotinib patent main driver filgotinib
filgotinib still major driver assum greater share ra ad
ipf pipelin asset gener signific sale assum
royalties/profit share sale filgotinib ra royalti
sale filgotinib crohn total filgotinib mileston payment
ad gener peak po adjust global sale
ipf gener peak po adjust global sale
filgotinib drive forecast strong contribut ad ipf
pipelin asset assum royalties/profit share sale
filgotinib ra royalti sale filgotinib crohn
total filgotinib development/commerci mileston
ad gener peak po adjust global sale
ipf gener peak po adjust global sale
filgotinib pipelin asset fail manag continu invest
 assum cash-per-share valu
overweight galapago
believ filgotinib addit pipelin
asset differenti take share
filgotinib differenti profil versu
oral competitor xeljanz
baracitinib believ best class
efficaci cleaner safeti profil
especi anemia addit posit
data gener crohn model peak
filgotinib sale ra crohn
earli data pipelin asset
ad ipf
encourag enough us incorpor
probabl adjust estim
molecul valuat await
main driver advanc
filgotinib ra ibd along continu
progress ipf ad program
risk achiev price
signific time phase ii profil
assur unknown side-effect larger
approv risk regulatori approv
assur potenti failur
gain approv one geographi
commerci risk ra market
competit number market
agent along agent develop
sovaldi/harvoni/epclusa/vosevi peak durat hcv sale hiv patent expir
sovaldi/harvoni/epclusa/vosevi peak durat hcv sale hiv patent expir
car-t drive risk-reward
car-t drive risk-reward
less rapid eros hcv franchis strong pipelin realiz drive bull
case hiv product revenu reach hcv busi gener
sale ww sale yescarta filgotinib
gilead respect
rapid hcv eros lower pipelin success bull case hiv
product revenu reach hcv busi declin sale
ww sale yescarta filgotinib
gilead respect
stabl hiv revenu quick hcv busi eros minim pipelin
success hiv product revenu hcv busi gener
sale littl pipelin valu
equal-weight gilead believ
offer signific absolut
upsid near-term catalyst
term upsid rel gilead
signific return capit share
repurchas low forward price-to-earnings multipl
offer downsid protect
believ hcv peak us
continu declin modestli
howev believ cash flow gener
robust believ row hcv
durabl long-term asset
hiv gilead done good job
switch nave patient new
stribild complera genvoya
truvada/atripla still hold market
right mean signific number
still need switch howev given time
solid taf switch data believ
least half market switch
car-t gilead acquisit kite provid
potenti renew long term revenu
main driver hiv franchis
hcv franchis car-t franchis car-
approv pipelin capit deploy
repres key driver
risk achiev price
unexpect competit hiv
rapid hcv eros
appreci consensu
failur car-t achiev signific
market penetr failur meaning
royalti contract revenu
net loss non-controlling interest
net incom gilead non-gaap
revenu share symtuza us
revenu share symtuza europ
total hiv hcv start
hcv exclud sovaldi start
equival
non-curr portion prepaid royalti
current portion long term debt
total liabil equiti
in-process research develop impair charg
tax benefit relat employe stock option
amort bond discount
chang oper asset liabil
accru liabil tax payabl
net cash provid use oper activ
purchas pp
net cash use invest activ
flow financ activ
proce issuanc common stock eso
excess tax benefit stock-bas compens
proce sale of/ payment settl warrant
proceeds/ purchas convert note hedg
proce credit facil
repay credit facil
issuance/ repay convert senior note net
proce from/ repay debt financ
contribut distribut non-controlling interest
repurchas common stock
net cash provid financ activ
effect exchang rate chang
chang cash
begin year
end year
market secur end year
clinic success market penetr drive risk/reward
clinic success market penetr drive risk/reward
peak penetr assum demonstr
abil modifi lt marker scd pain sickl crise thrombot event
new standard care assum limit competit gene therapi
peak penetr assum clinic success
compar success gene therapi gene therapi split
fail case assum residu cash valu
market signific unmet medic
need oral dose potenti
diseas modifi therapi posit well
compet market new therapi
decad market share suggest
us peak sale potenti
earli data compel initi
data demonstr reduct sickl
cell improv red blood cell
marker hemoglobin reticulocyt ldh
believ data could translat
clinic outcom includ reduct
sickl crise pain thrombot event
market assumpt leav room
competit current model
peak penetr hbss leav room
gene therapi believ oral dose
could prefer gene therapi could offer
cur therapi could
prefer patient
data competitor
regulatori progress
risk achiev price
clinic failur
greater success competitor molecul
gene therapi
unexpect safeti toler issu
patient complianc high
discount due signific medicaid
epidiolex ramp drive gw share
epidiolex ramp drive gw share
pt deriv dcf use discount rate
termin growth rate beyond valu
program cannabinoid base therapi rare neurolog
epidiolex exce expect drug ramp well label indic
dravet lenox-gastaut strong label use expect revenu
use gradual ramp expect revenu exceed
epidiolex ramp slower expect assum drug ramp well
label indic less steepli anticip off-label use minim
gw market leader medic
applic cannabis-rel intervent
sativex approv eu epidiolex
recent approv fda
transfer schedul
june year food drug
cannabidiol cbd oral solut
treatment seizur two rare sever
form epilepsi lennox-gastaut syndrom
dravet syndrom believ epidiolex
would wide use treatment
refractori pediatr epilepsi on-label
off-label
sale ramp epidiolex primari
driver share valu
risk achiev price
payer impos signific restrict
physician hesit prescrib
gwph adr british base
proprietari partner pipelin drive risk-reward
proprietari partner pipelin drive risk-reward
proprietari pipelin sale assum proprietari pipelin
sale flat modest increas spend
proprietari pipelin sale assum proprietari pipelin
sale flat modest increas spend
proprietari pipelin asset fail manag continu invest
assum cash-per-share valu
underweight given
kadcyla remov valuat given
royalti deal proprietari
pipelin key driver valuat
see risk clinic
develop plan assum
make market resist ovarian cancer
assum option
pipelin program
proprietari pipelin model
peak sale off-set sg spend
see clinic develop
pathway long trial design
complic potenti beat chemo
low view proprietari pipelin
high risk given toxic seen
compound lack signific
partner pipelin attribut
valu partner pipelin
main driver advanc
proprietari pipelin partner
risk achiev price
better wors expect result
proprietari pipelin specif
better durat respons
lower toxic versu re-emerg ocular
toxic durat respons line
competit compani
includ mek inhibitor immunotherapi
ovarian cancer
unexpect toxic proprietari
pipelin pipelin histori
toxic especi eye toxic thu
increas toxic could downsid driver
pt base dcf use discount rate project free
cash flow base termin valu
onward use termin growth rate project revenu
lead product candid tnbc muc
bull case assum achiev greater adopt ww peak risk
adjust sale assum commerci treatment line
mtnbc acceler adopt muc er cancer
base case assum launch mtnbc addit
revenu stream earlier line muc er larg enter
assign risk adjust late line use howev assum
probabl success po front line use ww risk adjust sale
bear case assum fail receiv approv indic
stock trade cash valu
qverweight thesi driven
differenti standard
care late line metastat tripl neg
breast cancer expect asset receiv
approv singl agent use
robust data drive adopt area
believ obtain multipl
label expans increas asset total
address market studi front line
mtnbc muc er breast cancer could
approv commerci sale
opportun earlier line mtnbc
data pivot phii studi trophi
muc hormon breast cancer
risk achiev price
fail achiev approv
competit landscap target
therapeut mtnbc increas
failur achiev signific label
expans earlier line therapi
jak backbon modest pipelin success key ew thesi
modest pipelin success key ew thesi
deriv pt risk-adjust sum-of-the-part sop analysi
forecast expect revenue/profit drug/condit
combin assum wacc termin growth
deriv npv assign probabl factor
drug/condit reflect clinic regulatori risks/tim sum
risk-adjust npv add cash excess requir invest
commerci out-performance jakafi base case greater baricitinib
sale potenti success across pipelin includ front-lin gvhd
increas penetr myelofibrosi polycythemia vera continu
drive jakafi revenu peak sale modest baricitinib royalti
pipelin success
jakafi underperform appear unlik reach compani
peak guidanc baricitinib launch poorli assum minim valu
pipelin beyond jakafi iclusig olumi royalti
jakafi provid stabl revenu backbon
revenu grow annual
patent expiri driven continu uptak
myelofibrosi polycythemia vera
pipelin continu matur
mix success see success gvhd
asset pipelin could mix
success thu wait greater clariti
key valuat driver commerci
execut approv drug well
perceiv clinic regulatori risk
data pivot
trial jakafi gvhd
data pivot gravita trial
itacitinib gvhd
risk achiev price
jakafi uptak less anticip
baricitinib fail obtain approv and/or
jakafi fail gvhd label
pt includ jakafi sale myelofibrosi mf polycythemia vera pv
royalti jakavi sale europ iclusig sale all/cml europ royalti
baricitinib sale rheumatoid arthriti atop dermat jak use graft-versus-
host diseas gvhd usag b-cell malign includ
risk-adjust npv robust earli clinic pre-clin asset
well drug discoveri engin
exhibit risk-adjust valu molecul
valuat methodolog use risk-adjust sum-of-the-part methodolog valu
examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens
discount rate use discount rate line compani
termin growth rate model forecast revenu expens
opportun beyond anticip exclus period product
product ip beyond expiri assign termin valu
breo anoro success drive risk reward
breo anoro success drive risk reward
pt deriv dcf assum discount rate
breo anoro captur signific share market bull case
assum breo anoro characterist qd dose breo lack
ic anoro drive major share copd asthma
prescript given sluggish launch drug comfort
physician approv laba/icss see scenario unlik
model peak ww sale breo anoro
trelegi
breo anoro sluggish launch case assum breo
anoro gain modest share copd/asthma prescript model peak ww
sale breo anoro
trelegi dcf valu equiti stream royalti less net-
breo anoro falter commerci bear case assum breo anoro
fail gain commerci traction model ww sale breo
anoro trelegi
underweight see limit
upsid valuat impli
potenti gsk consolid royalti
interest breo/anoro
launch breo anoro
sluggish far
breo qd dose potenti complianc
advantag howev top-line result
breo phiii trial suggest profil similar
patient switch approv laba/icss
compet least initi
laba/ class mean growth anoro
expect maba/tripl combo
cannib sale breo anoro
patient need come laba/
lama/laba take one drug
key driver model includ
royalti breo launch
anoro launch
risk achiev price
breo and/or anoro may sell better
compani may potenti
busi develop transact may
penetr durat ali therapi key valuat driver
penetr durat ali therapi key valuat driver
pt deriv dcf use discount rate
termin growth rate revenu driver model ali
market penetr us japan refractori frontlin
mainten treatment ntm
ali launch us japan achiev
penetr respect refractori ntm popul major
patient take form mainten treatment also forecast low
doubl digit penetr frontlin popul us japan peak sale
respect
ali launch us earli japan reach
penetr respect refractori ntm popul less
modest frontlin penetr us japan peak sale
ali achiev commerci
overweight insm given robust
data ali refractori induc ntm
patient derisk approv also provid
modest assumpt chronic dose
opportun note current data argu
investig label
geograph expans japan provid
addit lever see substanti
foreign sale larger ntm popul
prioriti review fda advisori
prepar japan file pmda
follow-up data long-term extens
convert studi full data
risk achiev price
failur reach market restrict
label target small portion
poor long term durabl driven
dropout safeti signal less differenti
standard treatment
delay life cycl manag studi
need obtain robust mainten
spinraza grow focu shift tegsedi
spinraza grow focu shift tegsedi
pt deriv dcf use discount rate
termin growth rate beyond valu ioni advanc
driven revenu upsid across lead pipelin drug assum rapid
penetr spinraza thrombocytopenia concern physician
patient allow tegsedi success hit market appli modest pipelin
valu drug includ ionis-fxi
ionis-htt
spinraza tegsedi drive valu assum rapid spinraza penetr upon
launch tegsedi sale grow thrombocytopenia limit launch appli modest
pipelin valu drug includ ionis-fxi
apo -l ionis-htt
ioni unabl launch addit product base case scenario assum
spinraza sale fall short expect commerci challeng
emerg respect platform pipelin drug
long haul view antisens
promis drug develop
platform equal-weight ioni
believ safeti toler concern
like remain overhang share
tegsedi launch underway expect
thrombocytopenia concern weekli
blood monitor could put damper
spiranza blockbust treatment
type sma tegsedi like increas
focu drug launch
thrombocytopenia particular --
challeng tegsedi like cap
upsid ioni share
spinraza continu grow spinal
muscular atrophi sma increas
emphasi type patient investor remain
wari compet gene therapi novarti
compound ioni share would driven
compani extens develop
pipelin numer near- medium-
risk achiev price
news flow regard either success
failur ioni pipelin could lead
swing share valu
data ioni pipelin alter
efficaci and/or safeti profil
clinic data competit program
alter dynam market ioni
current pursu
use wacc termin growth rate
linzess becom domin player ib cic market linzess
prefer treatment ib cic domin prescript product
take greater share over-the-counter therapi reach net sale
linzess steadi grower linzess gradual grow share ib cic market
beat brand player make headway expens
over-the-counter therapi net sale estim come
linzess slow ibs-c cic market slow tough competit take share
underweight ironwood
expect linzess might fall short
net sale expect addit
on-going price competit headwind
though ironwood multipl product
pipelin seen data point
give us confid long term
propos spin could help
realiz valu long-term growth
prospect appear limit view cap
key revenu driver model
risk achiev price
linzess sale could pick enabl upsid
versu street estim
one compani pipelin drug could
achiev superior data lead us
increas expect regard
activist investor win board seat
could potenti lead upsid move
durabl data wet age-rel macular degener drive risk/reward
durabl data wet age-rel macular degener
pt deriv dcf use discount
rate revenu driver model kodiak lead anti-vegf
candid retin diseas
commerci multipl retin diseas strong uptak
commerci wet diabet eye diseas peak
penetr probabl success po total risk-adjust
revenu grow
commerci limit set retin diseas modest
uptak commerci wet peak
penetr total risk-adjust revenu grow
peak
fail kodiak unabl develop trade cash
overweight thesi base
success commerci
sever compani commerci
anti-vegf therapi treatment
retin diseas burden monthli
bimonthli treatment reduc long
design extend therapeut
durabl compar current therapi
preclin data well-establish rabbit
model demonstr extend durabl
clean safeti profil
initi clinic data direct phib
phii interim analysi demonstr
demonstr efficaci durabl
wet diabet eye diseas
multipl studi begin
risk achiev price
investor question valu
increas toxic advanc patient
posit data competitor could weigh
market share especi
competitor data arriv prior pivot trial
pt deriv dcf use discount rate
termin growth rate beyond valu loxo advanc
larotrectinib use broadli front line larotrectinib approv trk fusion
cancer promptli see predomin usag front line loxo-
approv sampl front line usag
larotrectinib approv time drug approv varieti trk
fusion associ cancer achiev penetr front-lin refractori
set risk-adjust approv timelin bull
case see predominantli refractori usag
larotrectinib achiev modest sale drug receiv regulatori approv
achiev modest sale refractori set sale reach
ow thesi base potenti
differenti asset
key upcom data
clinic data larotrectinib
demonstr therapi achiev
high level clinic respons clean
safeti profil target trk fusion rare
genet alter play role tumor
trk fusion rare like yield
premium price potenti front line
opportun rel patient popul
larotrectinib primari driver valu
like fda approv come later year
initi becom increasingli
import loxo valuat ret
updat like come june
risk achiev price
either larotrectinib data
similar therapi target ret
larotrectinib approv find patient
could remain challeng could limit
potenti market opportun
loxo current strong financi
posit delay larotrectinib could
establish need addit fund
would depend upon market condit
wait margituximab phiii data posit updat proprietari dart
wait margituximab phiii data posit updat proprietari dart
bispecif platform drive valu
bispecif platform drive valu
strong uptak margituximab enoblituzumab bull scenario assum
sale treatment breast gastric cancer scenario also
assum enoblituzumab achiev success trial launch
treatment multipl solid tumor includ pipelin valu potenti
margetuximab peak margetuximab achiev modest success
studi find place nich therapi refractori breast cancer patient
includ pipelin valu potenti dart platform
failur commerci proprietari partner program macrogen
gener product relat revenu
equal-weight macrogen
macrogen one pure play
biotech broad bispecif antibodi
platform though believ platform
substanti potenti would like
see ampl data appli higher
like efficaci treatment cancer
manufactur packag dart
broadli applic implement
beyond oncolog effort underway
treat autoimmun infecti
diseas dart could effect safeti
toler issu could present
program offer support
valuat though modest
expect margetuxemab direct
valid target could yield
sale provid downsid support
respect target enoblituzumab
think could offer greatest util
combin checkpoint inhibitor
would like see data
increas expect
clinic data dart bispecif
antibodi beyond
updat phase compound
margetuximab bolster downsid
support valuat
clinic updat includ
risk achiev price
pipelin failur partner proprietari
neg safeti efficaci data
therapeut program
poor data bispecif program
cast doubt bispecif overal
program ohcm nhcm dcm drive risk/reward
program ohcm nhcm dcm drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth rate assum peak us
market share ohcm nhcm dcm
translat peak us sale respect
adjust use probabl success po ohcm
po nhcm po dcm
higher po dcm nhcm assum higher po dcm
nhcm follow posit data readout
sale estim base conserv market share risk-adjust
base case assumpt describ price target methodolog
precis medicin platform fail unabl advanc product
candid trade cash value-per-share
overweight myokardia
well-defin subgroup unmet medic
need potenti grow beyond
promis phase data
gener lead asset mavacamten
show reduct left ventricular outflow
tract lvot gradient week
provid opportun upsid
enter clinic advanc
phase data dcm
nhcm
ohcm
risk achiev price
poor efficaci concern safeti data
maverick-hcm lower
probabl success nhcm
concern safeti data
phase prevent advanc
pt deriv dcf use discount rate
termin growth rate beyond valu nabriva antibiot
lefamulin achiev strong ramp inpati outpati set drug
achiev peak sale contepo exce expect exceed
sale expect gener might enter market
lefamulin achiev modest share iv use lead oral use discharg set
risk adjust lefamulin sale expect reach
contepo approach risk adjust sale
antibiot unabl get approv stock valu cash
lefamulin novel mechan action
provid need option cabp nabriva
lefamulin first-in-class system
pleuromutilin develop oral iv
use treat community-acquir bacteri
pneumonia cabp lefamulin cabp
target spectrum activ novel
mechan action resist seen
date provid import altern
option treatment cabp
expect gradual commerci adopt
lefamulin sale driven use
inpati set nabriva initi
target inpati set sale
rep target highest
prescrib hospit repres
would key highli competit
lefamulin sale
acquisit zavant add second first-
in-class antibiot portfolio contepo
first-in-class epoxid could
potenti approv cuti although
opportun somewhat modest project
peak risk adjust sale
key valu driver perceiv clinic
regulatori risk lefamulin
risk achiev price
process could challeng
lefamulin and/or contepo sale fail
potenti addit dilut financ
pt base dcf base case forecast
metastat melanoma nsclc bladder cancer use
discount rate termin growth cash flow
higher probabl success greater market share assum
probabl success immunogen tumor melanoma
ncslc bladder less immunogen tumor also assum higher
market share versu base assum peak sale
risk-adjust success assum probabl success
immunogen tumor melanoma ncslc
bladder less immunogen tumor assum peak sale
fail clinic develop assum cash valu
overweight neon therapeut
believ neoantigen relev vaccin
target believ improv
efficaci tradit immun target
agent
initi data support immun
respons impact vaccin week
follow-up import determin
manag industri
platform informat need produc
person vaccin
phi data combo
opdivo
phi data
combin kaytruda
chemotherapi
phi initi
risk achiev price
failur initi clinic
neoantigen approach
mrna superior peptid approach
neoantigen screen technolog still
novel neon platform may sub-optimal
compar other may select
wrong neoantigen lead poor efficaci
overweight thesi driven ingrezza
even though question
whether growth slow think
possibl achiev peak sale despit
continu declin growth
end-of-phas meet
risk achiev price
ingrezza sale growth td may continu
deceler
neg clinic data
pt deriv dcf use discount
rate assum peak us market share td also model
peak us market share opicapon parkinson translat
ingrezza sale growth beat expect assum peak market share
addit assum po opicapon parkinson
unadjust us ingrezza sale td base case assumpt
detail price target methodolog
slower growth td sale opicapon fail gain approv bear case
assum probabl success opicapon parkinson also
assum lower peak us market share ingrezza td vs base case
assumpt translat peak sale
andexxa becom standard care bleed model detail follow
andexxa launch us eu andexxa use
major bleed peak ww sale
andexxa major driver valuat model detail follow
andexxa launch us eu andexxa use
major bleed peak sale
andexxa achiev base case peak sale assum andexxa
slow ramp modest us penetr andexxa ww sale peak
ew base key unknown
risk associ launch andexxa
await addit formulari
andexxa remain limit
manufactur approv allow full us
eur launch
need physician support
factor xa antidot consider bleed
signific potenti devast
complic anticoagul
revenu driver model
launch andexxa us eu row
risk achiev price
andexxa could launch poorli
obtain signific uptak physician
andexxa could receiv requir
program osteoporosi drive risk/reward
program osteoporosi drive risk/reward
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model tymlo osteoporosi risk adjust sale
elacestr neg metastat breast cancer
market leadership growth osteoporosi limit pressur forteo
gener risk-adjust elacestr bull case assum tymlo pen
patch achiev acceler switch forteo user minim impact
gener ww peak sale
pen patch elacestr respect
competit uptak tymlo commerci long term market
transfer patch probabl success po elacestr base
case assum tymlo obtain competit formulari posit
also commerci patch assum modest
pressur forteo gener assum gener price line
tymlo ww sale tymlo pen patch elacestr
respect
loss treatment popul forteo gener poor commerci
patch elacestr fail bear case assum tymlo pen increasingli
pressur entri multipl forteo gener patch fail
substanti grow anabol market ww peak sale
pen patch respect
overweight radiu compani
osteoporosi platform gener solid
data commerci pen earli sign
encourag launch lead us believ
tymlo captur sizeabl portion
anabol market formulari win
market transfer tymlo pen
tymlo patch establish sticki
patient popul face forteo
gener see tymlo brand
abl achiev share peak
addit program breast cancer
contribut signific upsid valuat
believ demonstr
encourag data current standard
trend formulari coverag tymlo
snda submiss multipl
updat global phii trial elacestr
breast cancer trial
time launch price potenti
risk achiev price
disappoint launch trajectori tymlo
track prescript data formulari
elacestr requir addit trial
fail demonstr improv
standard care
failur defend market share
gener includ inabl bring patch
market
eylea dupix i/o pipelin drive risk-reward
eylea dupix i/o pipelin drive risk-reward
better dupix penetr atop dermat asthma assum
us eylea row eylea sarilumab us
sale us dupilumab sale also
assum injunct place sale praluent
sarilumab me-too compar actemra strong dupix penetr
asthma atop dermat assum us eylea
row eylea us sarilumab sale
us dupilumab sale assum probabl
injunct sale praluent
praluent remain market sarilumab still me-too
modest dupix launch eylea face greater branded/biosimilar
competit assum us eylea row eylea
contribut praluent given complet injunct
modest row praluent sale sarilumab us
sale dupilumab sale
equal-weight regeneron
investor heavili scrutin dupix
prescript data sinc launch atop
dermat ad april believ
consensu still factor substanti sale
dupix ad well asthma see
risk/reward skew slightli
posit given steadi launch
dupix emerg pipelin i/o
see littl room near-term beat vs
dupix launch trajectori
project dupix sale
across atop dermat asthma
praluent factor watch
develop new trial proceed
sanofi/regeneron
 whether reduc price outcom
data inflect uptak
kevzara sarilumab see kevzara
me-too forecast sale
main driver dupix dupilumab
eylea i/o praluent kevzara sarilumab
risk achiev price
unexpect flatten dupix
continu sluggish sale praluent
competit success wamd space
contract research revenu
collabor manufactur
regeneron share profit/loss zaltrap commerci activ
reimburs regeneron research develop expens
profit/loss connect commerci antibodi
sanofi reimburs regeneron sell expens
up-front payment sanofi acquisit right relat two antibodi
off-set reimburs cost
reimburs regeneron research develop expens
profit/loss connect commerci
reimburs regeneron research develop expens
cost-shar regeneron eylea develop expens
regeneron net profit connect eylea exu commerci activ
reimburs regeneron research develop expens
contract research revenu
cash equival
prepaid expens current asset
properti plant equip net
account payabl accru expens
defer revenu sanofi
defer revenu
defer revenu sanofi
defer revenu
accumul comprehens income/loss
total liabil equiti
depreci amort
loss extingush debt
non-cash charg expens net
chang oper asset liabil
chang inventori
prepaid expens current asset
account payabl accru expens liabil
net cash produc use oper activ
purchas available-for-sal secur
matur sale available-for-sal secur
increas restrict cash market secur
net cash provid use invest activ
proce facil leas oblig
payment facil capit leas oblig
proce issuanc convert note
proce issuanc warrant
payment purchas convert note hedg
proce issuanc common stock
payment stock tender employe tax oblig
excess tax benefit stock-bas compens
net cash provid financ activ
chang cash
begin period
end period
success use
success use partner proprietari program drive
technolog partner proprietari program drive
pt deriv dcf use discount rate
termin growth rate beyond valu
proprietari partner gene therapi program
commerci proprietari partner program model
strong uptak indic proprietari program
hofh mp wet respect gener peak
sale partner program mp iiia sma partnership
ultragenyx dimens dmd gene therapi sale gener peak
royalti revenu
commerci proprietari partner program model
modest uptak indic proprietari program
hofh mp wet respect gener peak
sale partner program mp iiia sma partnership
ultragenyx dimens dmd gene therapi revenu gener peak
royalti revenu
failur commerci proprietari partner program
receiv royalti avexi gener product relat
revenu bear case consist cash value-per-share well valu
royalti novartis/avexi sma program eu
overweight
believ compani technolog
platform alreadi broadli licens
across gene therapi landscap provid
potenti transform method
safe effect deliv gene
present known target clear endpoint
reduct hofh reduct
gag accumul mp mp ii
arrang de-risk regenxbio
platform help reduc binari risk
face tradit gene therapi compani
success licens program use
vector deliveri method
reduc technic risk face proprietari
recent posit gene therapi data
help de-risk broader gene therapi
data/upd wet
hofh program
advanc
program mp mp ii respect
updat avexi sma program
technolog license
risk achiev price
pipelin failur partner proprietari
neg safeti efficaci data gene
therapi program develop
either technolog license gene
therapi compani use vector outsid
platform
pt deriv dcf use discount rate
termin growth rate beyond valu rhythm program
orphan genet disord obes
setmelanotid approv launch pomc null lepr defici
setmelanotid data bardet-biedl syndrom bb alstrm
suggest drug could exceed expect indic rais
confid combin phiii trial
setmelanotid like reach market pomc null lepr
defici data bardet-biedl syndrom largest valu driver
model appear promis await data move risk
adjust higher incorpor alstrm risk
adjust estim peak sale setmelanotid
setmelanotid fail reach market rhythm trade cash
compel efficaci setmelanotid
two ultra-orphan diseas may result
setmelanotid underway data
expect studi
success would enabl regulatori
bardet-biedl signific
opportun rhythm pursu bardet-biedl
syndrom alstrm syndrom
addit indic rhythm present
data indic suggest
setmelanotid could offer benefit
patient phiii trial examin
indic set begin later year
increas rate diagnosi upon launch
key challeng import lever
setmelanotid commerci success
view increas test diagnosi
rate genet disord obes
patient target ideal candid
setmelanotid therapi current
undiagnos anticip
avail therapeut target
increas test diagnosi rate
believ rhythm would need invest
meaning captur patient
realiz potenti market opportun
key valuat driver perceiv clinic
regulatori risk setmelanotid
syndrom pomc heterozyg obes
risk achiev price
fail clinic trial setmelanotid
rhythm unabl enrol pivot trial
orphan indic
potenti dilut financ
initi rct data diseas ind file drive risk/reward
initi rct data diseas ind file drive risk/reward
pt deriv dcf use discount
rate termin valu onward base
termin growth rate valuat assign credit rubiu rare
diseas oncolog platform
commerci rare diseas oncolog immunolog strong
uptak commerci rare diseas pku gout
homocystinuria oncolog nsclc immunolog pemphigu vulgari
probabl success po pku gout
homocystinuria nsclc pemphigu vulgari total risk-adjust
revenu grow
primari revenu contributor peak pku gout
commerci rare diseas oncolog modest uptak
commerci rare diseas pku gout homocystinuria
nsclc within oncolog pku assign po gout homocystinuria
valu po nsclc assign po pku
commerci product candid launch
total risk-adjust revenu grow
peak primari revenu contributor peak
pku gout
red platform fail rubiu unabl rct product candid
trade cash value-per-share
overweight thesi base
broad safe potenti applic
rubiu red platform could gener
diseas oncolog immunolog
pose white blood cell therapi like car-
includ broader applic off-the-
shelf approach improv safeti
rapid scalabl manufactur
preclin data encourag
date particularli rare diseas
platform ind lead product
candid phenylketonuria pku
expect file key risk
across rubiu rare diseas program
deliveri risk believ posit
initi data patient would
address investor concern significantli
derisk rare diseas program includ
refractori gout homocystinuria
ind file lead product candid rtx-
pku follow initi
interim data patient
subsequ ind file futur rct
product candid
poor safeti and/or efficaci data rtx-
would like caus investor question
rubiu abil gener effect
investor may subsequ question
valu red platform assign limit
valu rare diseas oncolog
short circul time would
impair commerci prospect
platform could lead limit efficaci
posit data competitor either
platform compani
weigh rubiu share especi
competitor data arriv prior meaning
dataset rubiu
brexanolon launch primari valuat driver
brexanolon launch primari valuat driver
brexanolon launch steep trajectori provid
bulk valuat strong launch mdd bipolar
insomnia
brexanolon launch provid bulk valuat
launch mdd bipoloar insomnia
brexanolon approv approv mdd bipolar
insomnia launch modest
brexanolon approv asset
global peak sale potenti clear
unmet need form basi valuat
clear upsid driver
derisk data mdd
potenti much broader profil post-
parkinson diseas addit
indic multi-billon dollar
pipelin broad continu offer
new drug extens effort target
gaba nmda
brexanolon key near-term driver
potenti launch howev
form bulk valuat
neg safeti efficaci data
therapeut program
unexpect delay clinic
potenti intellectu properti
challeng could impact futur revenu
long-term prospect sarepta dmd franchis drive valu
long-term prospect sarepta dmd franchis
pt deriv dcf use discount rate
termin growth beyond valu sarepta dmd franchis
bull scenario assum exondi achiev rapid launch sale
taper peak penetr achiev also assum aggress sale
exon approv well signific updat genetherapi
lgmd add upsid
base case scenario assum continu strength exondi well
approv golodirsen camisersen modest risk adjust
intern sale assum success genetherapi
assum lower peak penetr exondi approv golodirsen
modest sale approv camisersen downstream eros usag
includ revenu altern mutat
overweight thesi base
strong initi dmd genetherapi data
manag abil captur signific
market share dmd genetherapi
product genetherapi remain riski
believ initi data derisk program
provid signific upsid potenti
base busi exon skip drug
pipelin larg divers offer lgmd
potenti upsid driver
time market clinic success
risk achiev price
updat dmd genetherapi program
includ risk relat manufactur
on-going regulatori discuss
failur secur addit regulatori
approv obtain reimburs could
data competitor compani could
either posit neg impact
sarepta posit dmd market
success develop entinostat combo i/o
success develop entinostat combo i/o therapi hr breast cancer
therapi hr breast cancer
drive risk/reward
drive risk/reward
assum entinostat achiev rapid uptak hr bc strong uptak
combin i/o therapi nsclc melanoma tnbc also assum
combin hormon therapi hr breast cancer exce base case
expect incorpor project risk adjust i/o combin
sale hr her- sale
assum bulk valu come entinostat combin i/o
therapi howev valuat base lower sale project
risk adjust i/o assum modest hr her- breast cancer sale
project risk adjust
assum entinostat fail achiev suffici clinic result either hr
her- breast cancer i/o combin studi
equal-weight syndax
develop class hdac entinostat
data combin
increas confid view select
program high risk effort addit
less confid posit os
key phiii note inabl file
like caus stock rang
bound come month
entinostat combin i/o agent
checkpoint inhibitor could offer
substanti opportun howev await
see data encor trial
consid combin best class
drug use combo hormon
therapi hr her- breast cancer
popul offer valuat backstop
investor lessen risk lucr i/o
add-on play combin reach
multipl data readout
three encor studi provid
insight potenti entinostat
combin studi drive share
progress free surviv os data
phase entinostat trial combin
aromasin potenti avail
success readout
varieti physician sponsor trial
could provid addit insight
entinostat therapeut properti
potenti succeed altern i/o
risk achiev price
neg safeti efficaci data
therapeut program
unexpect challeng checkpoint
inhibitor i/o therapi gener
could dampen syndax opportun
potenti intellectu properti
challeng could impact futur revenu
crysvita drive risk/reward
crysvita
pt deriv dcf use discount
rate model peak risk-adjust revenu addit
peak ww sale mepsevii crysvita
model peak unadjust ww sale
adjust use po
posit data readout better-than-expect launch assum
advanc follow posit phase data result assum
po over-the-counter addit assum better-than-expect launch
lead greater peak market share crysvita mepsevii
strong crysvita launch base case assumpt describ price
target methodolog
pipelin product fail bear case assum pipelin candid fail
lower peak penetr us
equal-weight rate base
belief expect strong crysvita
launch larg price share
although think crysvita like
blockbust amount recogn
ultragenyx significantli lower
compani divers pipelin
still number year away
reach market
data crysvita open label phase
data first cohort phase
clariti ema potenti
file lc-faod phase data
phase data over-the-counter defici
cohort
risk achiev price
launch mepsevii crysvita
posit approv lc-faod
mepsevii crysvita neg phase
data over-the-counter defici
probabl success anti-ag market well osteoarthr knee
probabl success anti-ag market well osteoarthr knee
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model osteoarthr addit program
success oa drive peak sale probabl success
coupl probabl success penetr anti-ag market
broadli
success oa drive peak sale probabl success
coupl probabl success penetr anti-ag market
broadli remain bull case
program fail valu compani cash
manag pioneer novel
biolog senesc cell
opportun deliv step-funct chang
treatment chronic diseas
preclin model support
impact sasp factor senesc
suggest benefit
remov senesc cell
oa offer proof-of-concept model
clear biomark clinic endpoint
initi oa data well follow-up
long-term chronic data
addit ind file follow-up
product includ eye
risk achiev price
biolog approach
novel initi program fail falter
investor like heavili discount
competit space
privat
initi oa program may right
target test snc follow-up
period dose period medicin may
long enough kinet
remov snc see therapeut
respons known human
base case forecast deriv explicit forecast
bcma actr product discount
better efficaci safeti signal solid tumor model peak sale
liquid tumor bcma myeloma posit initi data
allow us valu solid tumor opportun implicitli
higher termin valu
activ product use refractori
patient take share current approv car-t base
cleaner safeti profil model peak sale includ peak
base valu program fail
ow unum base view
technolog could provid
robust therapeut window compar
especi solid tumor
believ manag outlin
reason strategi deal toxic
encount initi phi studi
initi solid tumor data
addit data rituximab
sea-bcma
initi studi
advanc cancer initi data
addit data
studi rituximab
addit data
studi sea-bcma
risk achiev price
safeti issu compromis actr
lack clean safeti efficaci
lack differenti
activ
triplet approv
triplet approv uptak life-cycl manag oper margin drive
uptak life-cycl manag oper margin drive
penetr across cf medicin life-cycl extens extend
franchis bull case assum higher penetr tripl
therapi het/min homozygot patient initi tripl data
replic phiii therapi launch ww sale
het/min homozygot addit tripl data commerci
success key
risk-adjust tripl combo success mainten key cf franchis
life-cycl extens base case assum penetr orkambi
homozyg cf patient eventu switch captur
homozyg het/min market tripl combo risk-adjust peak ww sale
tripl combin therapi
modest orkambi uptak tripl combin fail achiev approv
het/min popul bear case assum row us
penetr orkambi homozyg cf patient peak ww sale
kalydeco monotherapi peak
overweight vertex believ
initi tripl data replic phiii
studi see vertex clear leader
cf therapi beliv manag
potenti deliv ep overtim
initi phi phii data tripl
het/min popul better
kalydeco-lin efficaci
homozyg popul thu includ
risk-adjust tripl combin revenu
base case
believ potenti
competit believ vertex
signific advantag posit
on-market doubl combin in-
share competitor long-
main driver vertex phiii
tripl studi time approv launch
uptak current therapi
orkambi/kalydeco uptak in-
develop therapi tez/iva triplet
risk achiev price
combo penetr fall short
kalydeco sale fail meet
data clinic candid
tripl combin fail meet expect
data competit exce
vy-aadc parkinson drive risk/reward
vy-aadc parkinson drive risk/reward
pt deriv dcf use discount
rate assum peak market share advanc
parkinson moder parkinson translat unadjust
ww vy-aadc revenu risk-adjust use po
clariti regulatori path support file phase scenario
assum compani abl file phase data
requir addit patient result vy-aadc would reach
market
us launch base case assumpt describ price target
methodolog
gene therapi platform fail bear case assum voyag unabl
advanc product candid trade cash value-per-share
equal-weight rate base lack
catalyst late
earli parkinson data show promis
question remain durat respons
data multipl preclin program
year-end like lower impact
share de-risk data
program avail number
year
select lead candid freidreich ataxia
file ind applic al
huntington friedreich ataxia
vy-aadc phase data parkinson
vy-aadc phase data parkinson
risk achiev price
upsid risk posit parkinson data
huntington diseas al friedreich
downsid risk disappoint data
result earli stage candid
advanc clinic vy-aadc phase
phase studi may succeed
dasiglucagon glepaglutid driver
dasiglucagon glepaglutid driver
pt deriv dcf use discount rate
glepaglutid dasiglucagon demonstr superior profil product
differenti sb hypoglycemia respect lead acceler
uptak versu current standard care
dasiglucagon glepaglutid competit pipelin asset
approv view competit standard care
late state pipelin falter dasiglucagon glepaglutid fail reach
strong pipelin support ow rate
view zealand strong pipelin
led two therapi glepaglutid
dasiglucagon improv version
standard care drug
dasiglucagon could better offer
dasiglucagon rescu medic
sever hypoglycemia repres
conveni offer current market
glucagon like drive strong uptak
therapi approv potenti futur use
artifici pancrea system orphan
repres upsid estim
glepaglutid next-gen
could improv profil teduglutid
earlier featur short half
life requir complex multi-step
reconstitut process prior administr
glepaglutid enhanc stabil
extend half life allow drug
glepaglutid dasiglucagon success
risk achiev price
fail clinic trial pipelin candid
dasiglucagon glepaglutid
potenti need rais dilut equiti
